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A2M alpha-2-macroglobulin
ACT alpha-2-antichymotrypsin
AP alkaline phosphatase
API alpha-1-protease inhibitor
AMARC alpha-methylacyl-coenzyme A racemase gene
AR androgen receptor
ARE androgen responsive element
BPH benign prostatic hyperplasia
cDNA complementary deoxyribonucleic acid
CTC circulating tumor cells
DNA deoxyribonucleic acid
EGF epidermal growth factor
EST expressed sequence tag
HER-2/neu avian erythroblastic leukemia viral oncogene homolog 2 (ERBB2)
hK2 human glandular kallikrein 2
IGF-1 insulin-like growth factor 1
IS internal standard
kb kilobase
kD kilodalton
mRNA messenger ribonucleic acid
PCa prostate carcinoma
PCR polymerase chain reaction
PIN prostatic intraepithelial neoplasia
PSA prostate specific antigen
PSM/PSMA prostate specific membrane antigen
PTEN phosphatase and tensin homolog gene
qRT-PCR quantitative reverse transcription-polymerase chain reaction
RB1 retinoblastoma 1 gene
RNA ribonucleic acid
RP radical prostatectomy
RT-PCR reverse transcription-polymerase chain reaction
TNM tumor-node-metastasis
TRUS transrectal ultrasound
TURP transurethral resection of the prostate
7ABSTRACT
Occurrence of mRNA specific for a certain
tissue in peripheral blood is thought to indicate
the presence of circulating cancer cells and
metastatic spread of a tumor originating from
this tissue. The aim of this work was to study
the mRNA expression of prostate specific
genes in prostatic tissue as well as in blood
from prostate cancer (PCa) patients. As
prostate specific genes we studied prostate
specific antigen (PSA) and prostate specific
membrane antigen (PSM). We also
investigated the relative levels of human
glandular kallikrein (hK2) and PSA mRNAs
in malignant and benign prostatic tissue.
Expression of PSA mRNA in peripheral
blood was found by reverse transcriptase-
polymerase chain reaction (RT-PCR) in 9 out
of 18 PCa patients with metastatic disease but
in none of 7 patients without metastases.
Negative results in patients with metastatic
disease were associated with successful
endocrine therapy and low levels of serum
PSA, and the correlation between serum
concentrations of PSA and the presence of
PSA mRNA in peripheral blood was
statistically significant. PSA mRNA was not
found in four patients with benign prostatic
hyperplasia (BPH), other types of cancer or in
six healthy male and three female controls.
Thus the occurrence of PSA mRNA in
peripheral blood was associated with
metastatic PCa.
PSM mRNA was detected in blood from
18 out of 24 PCa patients and 12 out of 13
healthy donors and in the leukocyte fraction
of normal blood cells. PSM expression could
not be detected in erythroblasts, platelets, K-
562, U-937, HL-60 or Jurkat cell lines. Our
results indicate that sensitive nested RT-PCR
method detects PSM mRNA in the leukocyte
fraction of normal blood, which is probably
caused by a leaky promoter for the PSM
gene. Development of quantitative RT-PCR
assay to differentiate PSM mRNA expression
derived from circulating cancer cells from
background expression in blood cells seems
to be necessary in order to make PSM useful
for detection of PCa.
By using a quantitative RT-PCR (qRT-
PCR) method the influence of prostatic
surgery and endocrine treatment on prostatic
cells in circulation was studied in serial
samples. A competitive internal mRNA
standard was used for quantification of
absolute concentrations of PSA mRNA. The
detection limit of the assay was 7 copies of
PSA mRNA. Based on blood levels
measured from 88 control subjects the
cutoff level for circulating PSA mRNA was
defined as 26 copies per mL blood. A total
of 56 patients scheduled for biopsy, radical
prostatectomy (RP), transurethral resection
of the prostate (TURP), orchiectomy or total
androgen blockade were included in the
study. PSA mRNA levels in circulation
were measured before, during and up to 26
weeks after these procedures by a
quantitative RT-PCR method. Immediately
after RP or TURP, the PSA mRNA levels
increased in 27% and 29% of the samples,
respectively. Orchiectomy also caused a
moderate increase in 25% of the samples.
After prostate biopsy, two samples out of 15
became positive. Detectable PSA mRNA
levels became undetectable after 3 days to 6
months. No significant correlation was
found between PCR positivity and clinical
characteristics of the patients. The PSA
mRNA level varied from 26 to 956
copies/mL blood. At sensitivity levels close
to the detection limit the accuracy of
amplification based quantification and
detection systems is impaired by stochastic
factors arising during sampling. This
phenomenon is likely to explain the variable
results published in earlier reports.
Expression of hK2 and PSA is
regulated by similar mechanisms but
changes in their relative expression have
been observed in prostate cancer. We
therefore determined the relative levels of
PSA and hK2 mRNA in benign and
malignant prostate tissue using a
8quantitative method, in which mRNAs of
PSA and hK2 are reverse transcribed and
amplified in one reaction with the same
primers. The variation in the ratio of
hK2/PSA mRNA was remarkably small, the
difference between the highest and lowest
values being 3-fold, but the ratio of
hK2/PSA mRNA was significantly higher in
cancerous than in benign prostatic tissue.
This new quantitative RT-PCR technique
facilitates very accurate quantification of the
relative mRNA levels of similar genes.
91. REVIEW OF THE LITERATURE
1.1. PROSTATE CANCER
Prostate cancer is the most common cancer
in men in most industrialized countries
including Finland (Finnish Cancer
Registry, 2004) and the second most
common cause of cancer-related death in
men in the United States (Landis et al.,
1999). In Asian countries, the incidence
and mortality of prostate cancer is only 4%
of those observed in the U.S. (Whittemore,
1989). Factors other than genetic, e.g. diet,
have been suggested to be important in
promoting or preventing the development
of prostate cancer (Parkin and Muir, 1992).
Although 30-50% of men above the
age of 50 have microscopic prostate cancer
(Franks, 1956), only 9-11% develop
clinical disease and under 5% die of the
disease (Seidman et al., 1985). Clinically
insignificant cancers are typically found in
patients in their eight or ninth decade of
life. Distinct from this group are cancers
with aggressive growth pattern and
metastatic potential that develop in younger
patients (Albertsen et al., 1998).  A family
history of prostate cancer is found only in
5-10% of all prostate cancers (Carter et al.,
1992).
Over 98% of the prostate cancers are
epithelial adenocarcinomas (Dube et al.,
1973). The extent of prostate adeno-
carcinoma is described by the TNM (tumor,
node, metastasis) staging system (Table 1),
which takes into account the size of the
tumor within the prostate (T), the presence
of lymph node spread (N), and documented
evidence of the metastatic spread to other
organs (M) (Schroder et al., 1992; Vaughan
et al., 1998). Prostate cancer is graded on
the basis of the glandular differentiation
pattern of the tumor. The most widely used
system is the Gleason grading system
(Gleason, 1992) (Table 2). The most
common pattern of dedifferentiation is
assigned the primary grade and the second
most common pattern defines the
secondary grade. The Gleason score or
Gleason sum is obtained by addition of the
primary and secondary grade (Gleason and
Mellinger, 1974). Another grading system,
the WHO system, classifies the tumor into
three categories: well (G1), moderately
(G2) or poorly (G3) differentiated
(Mostofi, 1975).
Prostate cancer mostly gives rise to
clinical symptoms only after it has spread
through the prostatic capsule or has
metastasized to lymph nodes or bones.
Curative treatment of prostate cancer is
limited to the time, when the tumor still is
organ-confined. In most patients the
disease remains organ-confined for years
(Schmid et al., 1993). Especially for the
patients with rapidly progressing disease,
early diagnosis is important. Determination
of total serum PSA followed by biopsy is
the most common method for early
diagnosis of prostate cancer. Digital rectal
examination is also used but it has a low
predictive value and many clinically
significant cancers may be missed
(Schroder et al., 2000). By trasrectal
ultrasound (TRUS) it is possible to get a
more precise estimate of prostate volume.
TRUS is used to determine the size, shape
and internal echo image of the prostate
gland (Babaian et al., 1992a; Terris and
Stamey 1991; Watanabe et al., 1975). A
limitation of TRUS is the inability to reveal
pelvic lymph nodes, which can be observed
by computerized tomography (CT) or
magnetic resonance imaging (MRI).
Prostate cancer preferentially metastasizes
to bone. Radionuclide bone scan is the
primary method to detect bone metastases.
If serum PSA is below 10 µg/L, the risk for
bone metastases is <1% (Gleave et al.,
1996). A bone scan is recommended to
patients with bone pain, a PSA
concentration over 10 µg/L, or increased
concentration of serum alkaline
phosphatase (AP) (Suomen Urologiyhdis-
tys ry, 1999).
10
Table 1. The TNM system for staging of prostate cancer
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Clinically unapparent tumor
T1a Tumor found incidentally at TURP: 5% or less of tissue is cancerous
T1b Tumor found incidentally at TURP: 5% or more of tissue is cancerous
T1c Tumor found in prostate biopsy because of elevated serum PSA
T2 Palpable tumor confiend within the prostate
T2a Tumor involves half of lobe or less
T2b Tumor involves more than half of one lobe
T2c Tumor involves both lobes
T3 Tumor extends through the prostatic capsule
T3a Unilateral extracapsular extension
T3b Bilateral extracapsular extension
T3c Tumor involves seminal vesicles
T4 Tumor is fixed or invades adjacent structures other than seminal 
vesicles
T4a Tumor invades bladder neck and/or external sphincter and/or rectum
T4b Tumor invades levator muscles and/or is fixed to pelvic wall
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1-3 Regional lymph nodes
Distant metastases (M)
MX Presence of distant metastases cannot be assessed
M0 No distant metastases
M1a-c Distant metastases
References: Schröder et al. 1992, Vaughn et al. 1998
Table 2. The Gleason grading system of prostate cancer.
Grade Description
1 Simple round glands, close-packed in rounded masses with well-defined edges
2 Simple rounded glands, loosely packed in vague, rounded masses with loosely 
defined edges
3A Medium sized single glands of irregular shape and irregular spacing with ill-
defined infiltrating edges
3B Very similar to 3A, but small to very small glands, which must not form 
significant chains or cords
3C papillary and cribiform epithelium in smooth, rounded cylinders and masses; no 
necrosis
4A Small, medium, or large glands fused into cords, chains, or ragged, infiltrating 
masses
4B Very similar to 4A, but with many large clear cells, sometimes resembling 
"hypernephroma"
5A papillary and cribiform epithelium in smooth, rounded masses, more solid than 
3C and with central necrosis
5B Anaplastic adenocarcinoma in ragged sheets
Reference: Gleason 1992
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For organ confined prostate tumor
(T1-T2N0M0) the most effective therapy is
radical prostatectomy or radiotherapy
(Catalona et al., 1999; Shipley et al., 1999).
Due to the risk of complications, radical
prostatectomy is usually used only when
the expected lifetime of the patient is at
least ten years. Alternative therapy is
radical radiotherapy, which may be
curative also when the cancer has spread
locally outside the prostatic capsule (T1-
T3N0M0). If the tumor is well
differentiated and organ confined, 10-year
survival rate after radical prostatectomy or
radiotherapy is 90-94% (Catalona, 1994;
Lu-Yao and Yao, 1997). However, about
30% of patients initially diagnosed with
clinically localized prostate cancer, have
non-organ confined disease and suffer from
recurrent cancer after radical prostatectomy
(Partin et al., 1993).
The aim of radical prostatectomy is to
remove the cancer tissue entirely, but if the
disease is diagnosed when extraprostatic or
metastatic, hormonal therapy is mainly
used (Catalona, 1994). Well differentiated
prostate cancer cells are dependent on
androgens and endocrine therapy aims at
androgen deprivation of the tumor. This
can be achieved by orchiectomy or by
administration of estrogens, antiandrogens
or synthetic agonists of gonadotropin
releasing hormone (GnRH). However,
endocrine treatment usually leads to
androgen-independent disease within 3-5
years. This transition is thought to occur
through selection of androgen-independent
cells already existing in the tumor prior to
androgen deprivation (Isaacs and Coffey,
1981). The expected lifetime of patients
with metastases is 2-3 years, but if the
cancer is androgen-independent, it is less
than one year (Tannock et al., 1996).
In the past, the serum prostatic acid
phophatase (PAP) level was used as a
marker to detect prostate cancer. Although
somewhat useful in monitoring patients
with advanced disease, it has low
sensitivity in localized disease. In recent
years, examination of PAP has been
replaced by PSA (Seamonds et al., 1986;
Stamey et al., 1987).
Circulating tumor cells (CTC) can be
detected at extreamely low levels in the
blood of patients with carcinomas. The
number of CTC may represent tumor
burden, and changes in CTC numbers could
offer a way to evaluate the effectiveness of
a given treatment. The occurrence of CTC
has been studied in patients with various
cancers, including PCa, by using
immunochemical methods and recently
more by using RT-PCR to detect organ-
specific mRNA in blood.
1.2. PROSTATE SPECIFIC ANTIGEN
(PSA) AND HUMAN GLANDULAR
KALLIKREIN (hK2)
1.2.1. Genes, mRNAs and proteins
Prostate-specific antigen (PSA/hK3) and
human glandular kallikrein 2 (hGK1/hK2)
and the corresponding genes (KLK3 and
KLK2, respectively) belong to the human
tissue kallikrein gene family (Table 3)
(Lundwall and Lilja, 1987; Schedlich et al.,
1987), which comprises 15 tandemly
localized genes in chromosomal locus
19q13.4 (Diamandis and Yousef, 2002).
Tissue kallikreins form a subgroup in the
serine protease enzyme family. Of the 176
serine protease genes within the human
genome, this family represents the largest
continuous cluster (Puente et al., 2003).
Recently the first human kallikrein
pseudogene, YKLK1 has been identified in
the same locus (Yousef et al., 2004). The
sequence similarity between kallikreins at
the DNA and amino acid levels is 40-80%
(Diamandis and Yousef, 2002). The
similarity between the coding nucleotides
of KLK2 and KLK3 is 86% (Schedlich et
al., 1988), which is the highest in the
kallikrein family (Yousef et al., 2000). In
addition to the protein coding sequences,
the non-coding sequences, including 5’
ends and introns, are highly conserved in
KLK2 and KLK3 (Schedlich et al., 1987;
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Riegman et al., 1989; Lundwall, 1989).
Both genes have 5 coding exons and 4
introns (Riegman et al., 1989; Liu et al.,
1999). The PSA gene produces at least 13
and the hK2 gene 5 different mRNA
transcripts. They result from alternative
splicing or/and alternative polyadenylation
of these genes (Lundwall and Lilja, 1987;
Riegman et al., 1989; Monne et al., 1994;
Tanaka et al., 2000; Heuze et al., 1999;
Heuze-Vourc'h et al., 2003; Heuze-Vourc'h
et al., 2000; David et al., 2002; Schedlich et
al., 1987; Riegman et al., 1991; Liu et al.,
1999). The wild type PSA mRNA is 1464
bp and hK2 mRNA is 901 bp long. They
both code for glycoproteins with a 17
amino acid signal peptide and a 7 amino
acid propeptide, which is removed upon
activation of the proenzyme to the mature
237 amino acid protein (Lundwall and
Lilja, 1987; Schedlich et al., 1987).
1.2.2. Expression and function
PSA was first isolated from seminal plasma
and called gamma-seminoprotein (Hara et
al., 1971). Later it was isolated from
prostatic tissue and named PSA (Wang et
al., 1979). PSA and hK2 are mainly
expressed by the prostatic epithelium, and
the level of hK2 mRNA has been found to
be 10-50% of that of PSA mRNA in
normal prostatic tissue (Chapdelaine et al.,
1988; Henttu et al., 1990; Young et al.,
1992). In seminal plasma the hK2 levels
are only about 1% of the PSA levels
(Deperthes et al., 1995). Low level
expression of both genes has also been
found in other tissues like endometrium,
normal breast and breast cancer, pituitary
tissue and lung cancer (Clements and
Mukhtar, 1994; Diamandis et al., 1994; Yu
et al., 1996; Hsieh et al., 1997; Clements et
al., 1996; Levesque et al., 1995). In the
Unigene database it is also possible to find
expressed sequence tags (EST) encoding
PSA in the sciatic nerve, hematopoietic
stem cells (CD34+/38-), skeletal muscle
and brain (nervous tumor) as well as
adrenal gland and liver. ESTs for hK2 are
also found in the sciatic nerve, skeletal
muscle and hematopoietic stem cells
(http://www.ncbi.nlm.nih.gov/UniGene/).
By in situ hybridization, immunohisto-
chemistry and RT-PCR, PSA and hK2 were
recently found to be expressed also in
ileum, jejunum, epididymis, seminal
vesicle and skin (Olsson et al., 2005). PSA
and hK2 are up-regulated by androgens,
especially by dihydrotestosterone and the
synthetic androgen mibolerone (Young et
al., 1991; Young et al., 1992; Wolf et al.,
1992; Henttu et al., 1992). Androgens exert
Table 3. Human kallikrein gene family.
Gene    No. of transcript       Protein Other names Specificity
    variants
KLK1 3 hK1 hPRK trypsin-like
KLK2 5 hK2 hGK-1 trypsin-like
KLK3 13 hK3 PSA, APS chymotrypsin-like
KLK4 8 hK4 prostase, KLK-L1, EMSP1, PRSS17 trypsin-like
KLK5 5 hK5 KLK-L2 trypsin-like
KLK6 6 hK6 Zyme, Neurosin, Protease M trypsin-like
KLK7 3 hK7 HSCCE, PRSSL1 chymotrypsin-like
KLK8 4 hK8 Neuropsin, Ovasin trypsin-like
KLK9 2 hK9 KLK-L3 chymotrypsin-like
KLK10 1 hK10 NES1, PRSSL1 trypsin-like
KLK11 3 hK11 TLSP, Hippostasin, PRSS20 trypsin-like
KLK12 3 hK12 KLK-L5 trypsin-like
KLK13 8 hK13 KLK-L4 trypsin-like
KLK14 2 hK14 KLK-L6 trypsin-like
KLK15 5 hK15 Prostinogen, HSRNASPH trypsin-like
Modified from Borgono et al. (2004)
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their function via the androgen receptor,
which interacts with specific DNA
sequences (androgen responsive element,
ARE) in the PSA and hK2 genes (Carson-
Jurica et al., 1990). Mutations of the
androgen receptor (AR) gene in the human
prostatic adenocarcinoma cell line, LNCaP,
have been shown to cause expression of
PSA also by other steroids than androgens
(Montgomery et al., 1992).
The physiological function of PSA is
to digest the gel forming after ejaculation
(Lilja, 1985). Another possible role of PSA
is to cleave insulin-like growth factor
binding protein 3 (IGFBP-3) causing
release of insulin like growth factor 1 (IGF-
1), which can stimulate the growth of
prostate cancer (Cohen et al., 1991). PSA
has also been shown to degrade extra-
cellular matrix glycoproteins fibronectin
and laminin, which could facilitate invasion
by prostate cancer cells (Webber et al.,
1995). It may also facilitate bone
metastases by activating latent trans-
forming growth factor-beta (Killian et al.,
1993). PSA may on the other hand suppress
tumor growth by converting plasminogen
to biologically active angiostatin, a potent
inhibitor of angiogenesis (Heidtmann et al.,
1999). PSA has been shown to inhibit
endothelial cell proliferation, migration,
and invasion, which may explain, in part,
the naturally slow progression of prostate
cancer (Fortier et al., 1999). A role of PSA
as a tumor suppressor also is supported by
the finding that low expression of tissue
PSA is related to adverse prognosis (Stege
et al., 2000).
Active hK2 has the capacity to convert
the proenzyme form of PSA (pro-PSA) to
mature, enzymatically active PSA (Kumar
et al., 1997; Lovgren et al., 1997). HK2 can
also activate pro-hK2 suggesting that
maturation of pro-hK2 to enzymatically
active hK2 involves autoactivation
(Denmeade et al., 2001). In addition, hK2
has been shown to convert latent
prourokinase-type plasminogen activator to
active urokinase-type plasminogen
activator (uPA) and to inactivate its
primary inhibitor PAI-1 (Frenette et al.,
1997; Mikolajczyk et al., 1999). Further-
more, an increased expression of hK2 has
been observed in poorly differentiated
prostate cancer (Darson et al., 1999;
Darson et al., 1997).
1.2.3. Clinical aspects
PSA is normally secreted into seminal fluid
and only small amounts leak out into
circulation. The PSA levels in patients
without prostate cancer correlate with
prostate volume (Babaian et al., 1992b). In
cancer and BPH the tissue architecture is
lost and the release of PSA into blood is
increased (Bostwick, 1994). The serum
concentrations of total PSA are often
classified into three different ranges, 0-4
µg/L, 4-10 µg/L and >10 µg/L (Catalona et
al., 1991). Serum levels < 4 µg/L are
associated with low risk of prostate cancer,
but the cut-off limit 4 µg/L does not take
the effect of increasing prostate volume
with age on serum PSA into account, and
age-specific cut-off limits for PSA are also
used (Oesterling, 1996) (Table 4). PSA
levels ranging from 4 µg/L to 10 µg/L are
commonly referred to as the grey zone,
because elevated levels caused by BPH and
PCa overlap. Patients with PSA levels > 10
µg/L have a likelihood of more than 50%
of harboring prostate cancer (Catalona et
al., 1993).
When reaching circulation, active PSA
rapidly interacts with different protease
inhibitors such as alpha1-antichymotrypsin
(ACT), alpha2-macroglobulin (A2M)
(Christensson et al., 1990) and alpha1-
proteinase inhibitor (API) (Zhang et al.,
Table 4. Age-specific reference limits for PSA
Age (years) PSA (µg/L)
40-49 2.5
50-59 3.5
60-69 4.5
70-79 6.5
Reference: Oesterling et al. 1993
14
1997a). Most of the PSA in serum occurs in
complex with ACT and minor part with
A2M and API, whereas 5%-40% is free
(Stenman et al., 1991; Lilja et al., 1991).
Free PSA in serum has been found to
consist of proPSA containing 2, 4 or 7
amino acids of the propeptide and mature,
uncleaved free PSA as well as clipped form
of free PSA termed BPSA, which is
cleaved both after lysine 145 and lysine
182 (Mikolajczyk et al., 1997; Mikolajczyk
et al., 2001; Mikolajczyk et al., 2000a;
Mikolajczyk et al., 2000b; Wang et al.,
2000). Assays for total serum PSA measure
PSA-ACT, PSA-API and free PSA. The
concentrations of PSA in serum are often
increased by prostate cancer but moderately
elevated levels are mostly caused by BPH.
However, the proportion of PSA-ACT is
higher and proportion of free PSA is lower
in serum of prostate cancer patients than in
men with BPH (Stenman et al., 1991; Lilja
et al., 1991; Leinonen et al., 1993; Catalona
et al., 1995). The proportion of PSA-API
has also been found to be lower in men
with cancer than in those with BPH (Zhang
et al., 1999). The ratio of PSA-A2M to total
PSA is also lower in prostate cancer than in
BPH (Zhang et al., 2000). The proportion
of the various proforms of free PSA is
increased in cancer and this may improve
the detection of aggressive prostate cancers
in men with total PSA of 2-4 µ g / L
(Mikolajczyk et al., 2004; Catalona et al.,
2004). The BPSA form of free PSA has
recently been found to be a better predictor
of BPH than either total PSA or free PSA
(Canto et al., 2004) while PSA that is not
nicked at lysine 145 has been shown to be
more specific for prostate cancer
(Nurmikko et al., 2001; Steuber et al.,
2002)
Recently, it has been shown, that the
hK2/free PSA ratio in serum has a better
specificity without loss of sensitivity for
PCa than total PSA or the free/total PSA
ratio within the range of 4 to 10 µg/L of
total PSA. Among men prescreened with
PSA for prostate cancer, patients with high
hK2 concentrations have a five- to eight-
fold increased risk of prostate cancer. It has
also been reported that hK2 significantly
improves the identification of poorly
differentiated (G3) tumors compared with
PSA and is also helpful in the prediction of
organ-confined disease (Kwiatkowski et
al., 1998; Nam et al., 2000; Recker et al.,
2000; Haese et al., 2005). However, these
results have not been confirmed in other
studies (Partin et al., 1999; Bangma et al.,
2004).
1.3. PROSTATE SPECIFIC MEM-
BRANE ANTIGEN (PSM)
1.3.1. Gene, mRNA and protein
The gene encoding prostate specific
membrane antigen (PSM/PSMA) also
called folate hydrolase 1 (FOLH1) or
glutamate carboxypeptidase II (GCP2),
consists of 19 exons and it spans 62 kb of
genomic DNA in chromosome regions
11p11.2 (Rinker-Schaeffer et al., 1995;
Leek et al., 1995; O'Keefe et al., 1998;
Maraj et al., 1998). The mRNA sequence
of PSM is 2.65 kb and it encodes a 750-
amino acid type II transmembrane
glycoprotein of 100-kD (Troyer et al.,
1995). An alternative mRNA splice variant
of PSM mRNA, PSM’, is generated from
the mature transcript by use of an
alternative splice donor site at position 114
in the PSM cDNA sequence (Su et al.,
1995; O'Keefe et al., 1998). Translation of
PSM’ begins from a novel translation start
codon producing a protein that lacks the
first 57 amino acids coding for the
intracellular and transmembrane domains.
PSM’ codes for a protein of 95 kD, which
is localized to the cytoplasm (Su et al.,
1995; Grauer et al., 1998). Two other
splicing variants, PSM-C and PSM-D have
also been found (O'Keefe et al., 2001).
PSM-C begins transcription at the same
nucleotide as PSM and PSM’. It uses the
same splice donor site as PSM’, but unique
alternative splice acceptor sites located
within intron one of the PSM gene. PSM-C
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uses the same translation start codon as
PSM’ and would therefore produce a
protein that is identical to PSM’. PSM-D
has a new translation start codon within a
new exon and 24 novel amino acids and the
rest of the PSM gene protein in frame
(O'Keefe et al., 2001). In chromosome
11q14, there is a highly conserved dupli-
cation of the PSM gene, PSML (PSMA-
like), which possesses 98% identity to the
PSM gene at the nucleotide level (Leek et
al., 1995; O'Keefe et al., 2004).
1.3.2. Expression and function
PSM expression is highest in prostatic
tissue. With the anti-PSM monoclonal
antibody 7E11.C5 cytoplasmic immuno-
reactivity can be observed in benign
epithelium, cancer and lymph node
metastases. The expression increase from
benign epithelium to high grade prostatic
intraepithelial neoplasia (PIN) or adeno-
carcinoma, while the greatest extent and
intensity is observed in the highest grades
of cancer tissues. Furthermore, PSM
expression is hormonally modulated by
steroids and appears to be highest in
hormone-deprived states (Horoszewicz et
al., 1987; Israeli et al., 1994b; Bostwick et
al., 1998; Sweat et al., 1998). PSM mRNA
is down-regulated by androgens such as 5-
α-dihydrotestosterone and up-regulated by
growth factors such as basic fibroblast
growth factor (bFGF), transforming growth
factor-alpha (TGF-α ), and epidermal
growth factor (EGF) (Israeli et al., 1994b;
Kawakami et al., 1997; Wright et al.,
1996). Although highly expressed in
prostatic tissue, some other tissues also
show PSM expression. By RNase
protection assay expression has been found
in the brain, salivary gland, and small
intestine, but not muscle, kidney, liver or
mammary gland (Israeli et al., 1994b).
However, by sensitive nested RT-PCR,
PSM mRNA expression has been found
also in heart, liver, lung, spleen and kidney
(Renneberg et al., 1999). Small amounts of
PSM protein are additionally found in
membranes and cytosols of breast, ovary
and bone (Murphy et al., 2000). PSM
mRNA and protein expression is also found
in the endothelium of tumor-associated
neovasculature of multiple nonprostatic
solid malignancies (Liu et al., 1997; Silver
et al., 1997; Chang et al., 1999b; Chang et
al., 1999a). The PSML gene is expressed in
kidney and liver under the control of a
different promoter than the PSM gene, but
no expression has been found in the
prostatic tissue (O'Keefe et al., 2004).
Comparison of the expression of PSM
mRNA in benign and malignant prostatic
tissue shows 3 to 24-fold higher levels of
PSM mRNA in prostatic cancer than in the
normal prostate (Kawakami and
Nakayama, 1997; Stamey et al., 2001;
Burger et al., 2002; Schmittgen et al.,
2003). In contrast, normal human prostate
expresses more PSM’ than PSM. BPH
tissue shows similar expression of both
variants. The ratio of PSM to PSM’ mRNA
has been shown to be lowest in the normal
prostate and to increase with increasing
Gleason score being greatest in hormone-
refractory disease (Su et al., 1995;
Schmittgen et al., 2003). The expression of
the splicing variant PSM-C mRNA does
not differ between normal prostate, prostate
cancer and metastases. However, PSM-D
mRNA has been found to be 2- to 5-fold
higher in lymph node and bone metastases,
respectively, when compared to primary
prostate tumors. Expression is similar in
normal prostatic tissue and primary prostate
cancer (Schmittgen et al., 2003).
PSM is expressed in the prostate as a
noncovalently associated homodimer
(Schulke et al., 2003) and in the brain its
extracellular domain exerts NAALADase
activity cleaving the major neurotransmitter
N-acetyl-aspartyl glutamate (NAAG) to
yield N-acetyl-aspartate and free glutamate
(Carter et al., 1996). PSM cDNA from
human intestine has been cloned and both a
full-length transcript and a 93 bp shorter
transcript lacking exon 18 has been
identified (Devlin et al., 2000). Intestinal
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PSM has folate hydrolase activity cleaving
glutamate residues from folate (Pinto et al.,
1996). The role of the enzymatic activities
of PSM in the prostate is still unclear.
1.3.3. Clinical aspects
PSM protein has been found in serum
samples from prostatic cancer patients, in
the seminal fluid of normal donors, in
serum of BPH patients, and in normal male
sera. PSM has also been found in sera of
healthy females, and like in males, the
levels increase with age, with the highest
levels being found in sera from breast
cancer patients (Rochon et al., 1994;
Beckett et al., 1999). However, PSM levels
in prostate cancer patients have been found
by Western blotting and by protein biochip
immunoassay to be significantly higher
than in BPH patients or in normal controls
(Rochon et al., 1994; Xiao et al., 2001).
Elevated PSM levels in prostate
cancer have been found by enzyme-linked
immunosorbent assay (ELISA) to predict
clinical progression or resistance to therapy
(Murphy et al., 1995). PSM has also been
found to have prognostic significance,
especially in patients with metastatic
disease, and it correlates with the stage of
disease (Murphy et al., 1996; Murphy et al.,
1997).
In addition to Western blotting,
ELISA and protein biochip immunoassay,
PSM has been used in ProstaScint studies
(Cytogen Corp., Princeton, NJ). ProstaScint
utilizes the PSM antibody (7E11.C5),
which labeled with the gamma-emitting
111Indium has been used to image primary
and metastatic foci of prostate carcinoma.
This technique is approved by U.S. Food
and Drug Administration (FDA) in the
preoperative setting for patients with
prostate cancer who are at high risk of
metastatic disease and in patients with
prostate cancer with a rising PSA level
after prostatectomy (Sodee et al., 2000).
Prostascint has been found to be more
sensitive and accurate in detecting local or
regional lymph node spread than CT, MRI
and biopsy (Elgamal et al., 2000).
1.4. GENETIC CHANGES IN PROS-
TATE CANCER
The heterogeneity and multifocality of
cancerous prostatic lesions, together with
the relative small size of the prostate, make
it difficult to obtain enough homogenous
material for molecular analysis (Abate-
Shen and Shen, 2000). Furthermore there
are only a few prostate cancer cell lines
suitable for in vitro studies, probably
because of the slow growth of most
prostate tumors (Berges et al., 1995).
Additionally most commonly used cell
lines LNCaP, PC3 and DU-145 have been
isolated from metastatic lesions and not
from primary tumors (Horoszewicz et al.,
1983; Kaighn et al., 1979; Stone et al.,
1978). Most studies in the literature are
based on these cell lines, while the genetic
information from primary prostatic tumors
is still rather limited.
1.4.1. Germ line changes
The PSA gene has a polymorphic site in its
ARE I at position –158 with two alleles, A
and G. The GG genotype has been reported
to be associated with more advanced
disease at the time of diagnosis (Xue et al.,
2000; Gsur et al., 2002). Together with a
short glutamine repeat in the androgen
receptor the GG genotype was found to be
associated with significantly increased risk
of malignant disease in younger men (<65
years) (Binnie et al., 2004). Slightly, but
not statistically significantly lower PSA
levels has been found in men with the AA
genotype (Xu et al., 2002). Contradictory
results showing homozygosity for the A-
allele to be associated with higher serum
PSA levels and with the presence of
circulating tumor cells has been reported
(Medeiros et al., 2002). Recently Wang et
al. found no association between PSA ARE
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I polymorphism and prostate cancer risk or
serum PSA levels in Japanese men (Wang
et al., 2003). However, genetic variations
(single nucleotide polymorphism, SNP) in
the PSA promoter (-4643G/A, -5412C/T,
and -5429T/G) have been shown to be
associated with increased serum levels in
men without prostate cancer (Cramer et al.,
2003).
Single nucleotide polymorphism at
base 792C/T in the hK2 coding region has
been found. 792C form encodes the active
and 792T form encodes the inactive hK2
protein (Herrala et al., 1997). The inactive
T allele is associated with lower serum hK2
levels, but a higher prostate cancer risk.
This could be explained by lower baseline
levels of hK2 both in normal and malignant
prostate cells. Thus, increased hK2
production by prostate cancer cells would
have a more pronounced association with
prostate cancer risk for patients with low
baseline production of hK2 (i.e., TT
genotype) compared with patients who
have high baseline hK2 levels (i.e., CC
genotype) (Nam et al., 2003).
1.4.2. Somatic changes
At the chromosomal level losses of genetic
material are more common than gains or
amplifications in prostate cancer. The two
most common regions with deletions are 8p
and 13q (Porkka and Visakorpi, 2004). The
most promising target gene for the 8p loss
is a homeobox gene NKX3.1 (He et al.,
1997). Loss of protein expression of
NKX3.1 has been shown to correlate with
tumor progression (Bowen et al., 2000).
Although loss of the NKX3.1 gene locus
has been detected in prostate cancer, no
mutations have been found in the
remaining allele (Voeller et al., 1997). This
may indicate haploinsufficiency as a
mechanism abolishing the suppressive
activity of NKX3.1. In one study increased
expression of NKX3.1 mRNA has been
found in prostate cancer tissue compared to
normal tissue (Xu et al., 2000), which
could indicate posttranscriptional control of
NKX3.1 gene expression.
The second most frequently deleted
chromosomal region in prostate cancer is
13q. The retinoblastoma gene (RB1) at
13q14 is a strong candidate as a cancer
suppressor gene in this area, but
controversial results on the loss of the RB1
locus have been reported (Latil et al., 1999;
Chen et al., 2001; Ueda et al., 1999; Hosoki
et al., 2002). Other regions showing losses
in prostate cancer are 6q, 10q, 16q and 18q,
indicating the presence of possible tumor
suppressor genes in these regions (Porkka
and Visakorpi, 2004).
PTEN gene on 10q23 has been found
to be mutated in the prostate cancer cell
lines LNCaP and DU-145 (Li et al., 1997).
Deletions and mutations have also been
reported more frequently in metastatic
lesions of prostate cancer than in primary
tumors (Dong et al., 2001; Vlietstra et al.,
1998). Loss of heterozygosity (LOH) has
been reported to be more frequent than
mutations of PTEN  in prostate cancer
(Fernandez and Eng, 2002). Haploin-
sufficiency, where only one allele of PTEN
is inactivated and the gene product from the
remaining allele is insufficient to produce a
normal phenotype, has been shown to
promote prostate cancer progression
(Kwabi-Addo et al., 2001).
The most common genomic change in
prostate cancer is hypermethylation of the
glutathione S-transferase (GSTP1) gene
promoter, which is found in over 90% of
prostate tumors and in 70% of PIN cases
(Lee et al., 1994; Brooks et al., 1998).
Decreased expression of E-cadherin
and mitogen-activated protein kinase
kinase 4 (MKK4) proteins have been
reported to be associated with prostate
cancer metastasis (Umbas et al., 1992;
Yoshida et al., 1999). E-cadherin
expression has been found to be
significantly lower in tumor tissues which
were positive for PSA or PSM RT-PCR as
compared to RT-PCR negative tissues
(Mejean et al., 2000; Loric et al., 2001).
Expression of the cell cycle regulatory
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genes p27 and p16 has been found to be
altered in prostate cancer. P27 expression
progressively decreases with increased
tumor grade and stage (Tsihlias et al., 1998;
Cote et al., 1998), while P16 gene deletion
and methylation combine to inactivate the
gene in a subset of tumors and thus has
been thought to represent a late event in
prostate cancer progression (Jarrard et al.,
1997).
Prostate stem cell antigen (PSCA) is a
123 amino acid protein first identified as an
upregulated gene during cancer progression
in the LAPC-4 prostate zenograft model. In
the normal prostate, PSCA mRNA has been
detected in a subset of basal and secretory
cells (Reiter et al., 1998). It has been found
to be overexpressed at the mRNA and
protein levels in PCa and the expression
has been found to correlate with increasing
grade and stage of the tumor (Zhigang and
Wenlv, 2004).
DD3 gene has been reported to be one
of the most prostate cancer specific genes
at present (Bussemakers et al., 1999). It is
highly overexpressed in prostate cancer at
mRNA level and it is regulated by a unique
prostate cancer-specific transcriptional
mechanism. However, no correlation
between transcriptional activity and tumor
stage or grade has been detected (de Kok et
al., 2002).
When prostate cancer progresses from
a hormone-sensitive, androgen-dependent
stage to a hormone-refractory, androgen-
independent tumor, the androgen receptor
pathway functions despite anti-androgen
therapy. The androgen receptor has been
identified as a target gene for Xq
amplification that is frequently found in
hormone-refractory prostate tumors
(Visakorpi et al., 1995; Linja et al., 2001).
Polymorphism and mutations have also
been found in the AR gene. These have
been suggested to be associated with higher
prostate cancer risk and antiandrogen
t rea tment  fa i lu re ,  respec t ive ly
(Giovannucci et al., 1997; Taplin et al.,
1995; Hara et al., 2003). It has also been
shown that IGF-I, keratinocyte growth
factor (KGF), EGF and HER-2/neu directly
can activate the AR in the absence of
androgens, which means that the androgen-
signaling chain may be activated by growth
factors in an androgen-depleted
environment (Culig et al., 1994; Craft et al.,
1999).
Increased mRNA levels of alpha-
methylacyl-coenzyme A racemase
(AMARC) in relation to PSA have been
shown to be predictive of prostate cancer
(Zielie et al., 2004) and immuno-
histochemical staining for AMARC is now
used in PCa diagnosis (Jiang et al., 2001;
Rubin et al., 2002).
The Hedgehog signalling pathway,
which also plays an essential role in
developmental patterning, is required for
regeneration of the prostatic epithelium
(Karhadkar et al., 2004). Continuous
pathway activation has been shown to
transform prostate progenitor cells and
render them tumorigenic. Furthermore,
increased pathway activity has been found
to distinguish metastatic from localized
prostate cancer. Monitoring and
manipulation of the Hedgehog pathway
activity has been suggested to offer
significant improvements in diagnosis and
treatment of prostate cancer with metastatic
potential (Karhadkar et al., 2004).
Recently, a new candidate tumor
suppressor gene, E P H B 2  has been
identified in prostate cancer by nonsense-
mediated microarray analysis (Huusko et
al., 2004). The DU 145 prostate cancer cell
line has been found to carry a truncating
mutation of EPHB2 and a deletion of the
remaining allele. Additional frameshift,
splice site, missense and nonsense
mutations were found in clinical prostate
cancer samples. These findings suggest that
inactivation of EPHB2 may be important in
the progression and metastasis of prostate
cancer (Huusko et al., 2004).
Hepsin, a type II transmembrane
serine protease, is found to be over-
expressed in prostate cancer compared to
normal prostatic tissue and BPH tissue both
at the mRNA and protein levels (Luo et al.,
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2001; Magee et al., 2001; Dhanasekaran et
al., 2001; Stamey et al., 2001). The over-
expression has been shown to cause
disorganization of the basement membrane
and it also promotes progression of the
primary tumor and metastasis to liver, lung,
and bone (Klezovitch et al., 2004). A
significant correlation between the up-
regulation of hepsin and tumor grade has
been found, which suggests that hepsin
could be a prognostic marker for tumor
aggressiveness of PCa (Stephan et al.,
2004).
1.5. RT-PCR TECHNIQUES
The polymerase chain reaction (PCR) was
first proposed in the early 1970s by H.
Ghobind Khorana and his colleagues as a
strategy to lessen the labor involved in
chemical synthesis of genes (Kleppe et al.,
1971). However, at that time, when genes
had not been sequenced and thermostable
DNA polymerases had not been described,
the idea was quickly forgotten. The
technique was independently conceived 15
years later by Kary Mullis and coworkers,
who described in vitro amplification of
single-copy mammalian genes using the
Klenow fragment of Escherichia coli DNA
polymerase I (Saiki et al., 1985; Mullis et
al., 1986; Mullis and Faloona, 1987). The
use of a thermostable polymerase from
Thermus aquaticus (Saiki et al., 1988)
increased the efficiency of PCR and
enabled automatization of the method.
Shortly after the introduction of PCR,
Chelly et al. described the addition of
another step to the PCR technique, i.e., the
reverse transcription (RT), which made it
possible to amplify segments of mRNA
(Chelly et al., 1988). By RT-PCR,
complementary DNA (cDNA) copies of
RNA are amplified. The first step is the
conversion of RNA to a single-stranded
cDNA template by an RNA-dependent
DNA polymerase. The extension of a
cDNA copy starts from an oligonucleotide
primer hybridized to RNA and it can then
be amplified by PCR (Figure 1).
The advantages of RT-PCR over
traditional Northern blot analysis are
sensitivity, the need for only small
quantities of RNA and a shortened analysis
time. Additionally, RT-PCR can also
provide more accurate quantitative
information about mRNA levels. However,
it is a complex technique and considerable
attention should be given to its technical
aspects.
1.5.1. RNA isolation
The quality of the RNA template in RT-
PCR procedures is the most important
determinant of reproducibility, especially in
quantitative applications. It is therefore
important to handle samples carefully at
every stage, including collection,
transporting and storage. RNA is extremely
delicate once removed from its cellular
environment and care should therefore be
taken also in the purification step to avoid
degradation. It has been shown that the
amplification efficiency of different genes
is affected differently by RNA degradation
(Bustin and Nolan, 2004). Additionally, if
mRNA is partially degraded, the cDNA
yield is significantly lower near the 5´end
of the mRNA than near the polyA tail
(Swift et al., 2000).
Another important criterion for the
RNA used in qRT-PCR is the absence of
genomic DNA. DNA contamination causes
inaccurate quantification of total RNA
concentration and it can also inhibit the
RT-PCR assay (Bustin and Nolan, 2004).
There are also numerous components in
blood and tissue that can inhibit RT-PCR
assays, e.g, immunoglobulin G,
hemoglobin and lactoferrin (Al-Soud et al.,
2000; Al-Soud and Radstrom, 2001).
DNAse-treatment prior to RT and testing
RNA preparations for inhibitors increase
the accuracy of quantification by RT-PCR
(Bustin and Nolan, 2004).
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1.5.2. Reverse transcription
In the qRT-PCR the RT step is critical for
sensitive and accurate quantification and
the amount of cDNA must accurately
reflect the initial RNA content. It has been
shown that experimental variation in RT-
PCR is mainly attributable to the RT step.
Reverse transcription efficiency depends on
priming strategy, total RNA concentration
and the enzyme used (Zhang and Byrne,
1999; Stahlberg et al., 2004a; Stahlberg et
al., 2004b).
For the RT step specific primers,
random primers or oligo-dT primers can be
used (Figure 1). The advantage of oligo-dT
primers and random primers is, that they
maximize the number of mRNA molecules
that can be analyzed from a small RNA
sample. However, the majority of cDNA
synthesized from total RNA by random
primers is derived from ribosomal RNA
(rRNA). This may create problems if the
target mRNA is present at low levels.
Oligo-dT primed cDNA synthesis is more
specific as it does not transcribe rRNA.
However, it will not prime RNA lacking
the polyA tail or partly degraded RNA.
Therefore it is unsuitable for RNA isolated
from laser capture microdissected tissue or
from archival material (Bustin and Nolan,
2004).
The use of target specific primers has
been shown to be the most specific way to
produce cDNA. Up to 24-fold differences
have been measured by using gene specific
primers compared to random hexamers
(Stahlberg et al., 2004a). The main
disadvantage of this method is that it
requires different primers for each target.
Different reverse transcriptases
produce different amounts of cDNA from a
particular gene and up to 100-fold
differences have been observed. The
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Figure 1. Schematic representation of various methods for amplification of RNA by PCR.
GSP = gene specific primer.
21
concentration of total RNA and dithiotreitol
(DTT) during cDNA synthesis has also
been shown to be crucial for successful
quantification of mRNA (Stahlberg et al.,
2004a; Lekanne Deprez et al., 2002). Thus,
for quantificating gene expression by
reverse transcription, the same enzyme,
same priming strategy and identical
experimental conditions should be used.
1.5.3. Polymerase chain reaction
The polymerase chain reaction is dependent
on the specificity of the oligonucleotide
primers, the efficiency of the polymerase,
and the experimental conditions, of which
the primer specificity is most crucial.
Mispriming and primer dimerization can
signicantly affect the sensitivity of the PCR
reaction and should be avoided (Chou et
al., 1992). In RT-PCR, the primers should
span exon-intron boundaries to avoid the
amplification of genomic DNA.
A number of enzymes are available
for PCR amplification. They vary in their
fidelity, efficiency and ability to synthesize
large DNA products. The most commonly
used, Taq DNA polymerase, has 5’-3’-
exonuclease activity but lacks 3’-5’-
proofreading exonuclease activity making
it efficient but somewhat inexact. Mixtures
of two or more DNA polymerases can
significantly increase the fidelity while
maintaining the high efficiency of Taq
(Cline et al., 1996). However, the
proofreading activity can lead to primer
degradation from the 3’-end and the rate of
degradation is much faster for longer
primers (de Noronha and Mullins, 1992).
The PCR reaction also needs
deoxynucleotide triphosphates (dNTPs),
divalent cations (usually Mg2+) and
monovalent cations (KCl) in a buffer,
which maintains the right pH. Especially
the concentrations of Mg2+ and dNTP
should be strictly controlled. Mg2+ affects
enzyme activity and increases the melting
temperature (Tm) of double-stranded DNA.
Imbalanced dNTP mixtures will reduce the
polymerase fidelity and form soluble
complexes with Mg2+ producing a substrate
that the polymerase recoqnizes and
amplifies (Eckert and Kunkel, 1991).
1.5.4. Detection and quantification of
RT-PCR products
Qualitative detection of RT-PCR products
is conventionally made by gel electro-
phoresis with ethidium bromide staining,
but Southern blotting and/or sequencing of
the product may be required to confirm the
amplicon. Quantitative RT-PCR requires
that the whole procedure is quantitative,
i.e., isolation of the RNA, the RT and PCR
steps and the detection of the RT-PCR
products. Quantification also needs the use
of control/reference genes or calibrators.
The controls can be endogenous (e.g.,
housekeeping genes) or exogenous (e.g.,
synthetic DNA or RNA added to the
sample). Both endogenous and exogenous
controls can be either internal (amplified in
the same tube) or external (amplified in
separate tube). Different detection methods
and controls used in qRT-PCR are
discussed in following chapters.
1.5.4.1. Real-time quantification
Real-time PCR is a method that comprises
both amplification and quantification of the
PCR products simultaneously. Real-time
PCR offers fast analysis of samples and the
risk of post-amplification contamination of
samples is abolished. The detection
chemistries of all real-time PCR procedures
are based on one of two principles for
monitoring amplification products: binding
of dyes to double-stranded DNA or
hybridization of fluorescent probes to
single-stranded DNA. Small molecules like
SYBR Green bind to double-stranded DNA
as minor groove binders (Morrison et al.,
1998). Several approaches using target-
specific hybridization to single-stranded
DNA have been introduced, including
hybridization probes (Wittwer et al., 1997),
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TaqMan/hydrolysis probes (Holland et al.,
1991; Livak et al., 1995), molecular
beacons (Tyagi and Kramer, 1996) and
scorpions (Nazarenko et al., 1997;
Whitcombe et al., 1999) (Figure 2). The
detection of the signal in these techniques
is based on the fluorescence resonance
energy transfer (FRET), which is a
distance-dependent interaction between the
electronic excited states of two dye
molecules in which excitation energy is
transferred from a donor molecule to an
acceptor molecule.
Assays using two fluorescently
labeled probes are based on one probe
labeled with donor dye at the 3’-end and
the other one labeled with an acceptor dye
at 5’-end. When the amplicon is produced,
the probes hybridize adjacent to each other
within the amplified fragment and bring the
two dyes next to each other allowing
energy transfer between the dyes leading to
a change in the fluorescent signal (Figure
2B).
Technologies using hydrolysis probes
(for example Taqman), molecular beacons
and scorpions utilize a hybridization probe
with a reporter dye and a quencher dye at
their 5’- and 3’-ends, respectively. In the
Taqman technique, the probe is cleaved
during PCR by the 5’-activity of DNA
polymerase separating the dyes. Thus the
quenching no longer occurs, which leads to
a generation of a fluorescent signal (Figure
2C). When a molecular beacon hybridizes
to its target sequence of the amplicon, the
hairpin loop opens separating the dyes and
generating a fluorescence signal (Figure
2D).
The fluorescence of DNA dyes or
probes is monitored during each cycle of
the PCR. At a certain point during
amplification, the product accumulates to
increase fluorescence above the back-
ground. This point is defined as the
threshold cycle (Ct) and always occurs
during the exponential phase of
amplification. The relative copy number
between two samples (experimental and
control) can be determined by the
difference in their respective Ct values
(Higuchi et al., 1992; Gibson et al., 1996).
Methods using SYBR Green obviate
the need for target-specific probes, but the
specificity is determined entirely by the
primers. As any double-stranded DNA
generates fluorescence, additional speci-
ficity must be generated by plotting
fluorescence as a function of temperature to
generate a melting curve of the amplicon
(Ririe et al., 1997).
The use of target-specific probes
increases the sensitivity of real-time PCR
and enables multiplex approaches with
differentially labeled fluorescent dyes.
1.5.4.2. Endpoint quantification
In addition to real-time quantification,
several methods for quantification of
endpoint PCR products have been
described (Ikonen et al., 1992; Pannetier et
al., 1993; Alard et al., 1993; Karttunen et
al., 1996; Ylikoski et al., 1999). In endpoint
quantification the PCR products are not
measured during linear cycles, but after the
reaction has reached a plateau phase. This
is possible in the coamplification methods,
where the amplification efficiencies of the
templates are equal (Raeymaekers, 2000).
Thus their ratio will remain constant
despite the saturation of the reaction.
Minisequencing (single nucleotide
primer extension) utilizes the specificity of
DNA polymerase to incorporate a single
nucleotide at the 3’-end of a sequence
specific primer (Syvanen et al., 1990).
During amplification, the PCR product is
labeled using a biotinylated primer.
Following amplification, the PCR product
is captured on a streptavidin-coated solid
phase and quantitatively detected by
incorporating labeled nucleotides to a
target-specific primer annealed imme-
diately adjacent to the polymorphic site
(Figure 3). Tritium has been used as a
detection label in combination with
scintillating microtiter plates (Ihalainen et
al., 1994). Minisequencing has been used
for quantification of rare mRNA transcripts
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Figure 2.
 
Different detection methods for real-time RT-PCR using specific intercalating agents
like SYBR Green (A) or different techniques based on sequence specific labeled probes (B to F). 
From: Schrader et al. J. Urol. vol. 169: 1858-64 (2003).
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(Ikonen et al., 1992; Singer-Sam et al.,
1992) and relative levels of two highly
homologous transcripts (Karttunen et al.,
1996; Stenman et al., 2001). When
compared to assays using allele-specific
probes (ASO), the power of discrimination
between genotypes has been found to be
one order of magnitude higher using the
minisequencing method (Pastinen et al.,
1997).
Time-resolved fluorometry has also
been used for detection of quantitative RT-
PCR products either as single-label or dual-
label solution hybridization assays
(Verhaegen et al., 1998; Ylikoski et al.,
1999; Ylikoski et al., 2001a). Time-
resolved fluorometry (TRF) with lantanide
chelates is a very sensitive technique that
utilizes the long decay time and the large
Stoke's shift between excitation and
emission wavelengths of the lantanide
chelates (Syvanen et al., 1986).
Endpoint quantification for RT-PCR
products has also been made by agarose gel
electrophoresis or polyacrylamide gel
electrophoresis and ethidium bromide
staining followed by densitomety
(Mularoni et al., 1996; Bor et al., 1998). In
all endpoint quantification methods several
steps are needed in contrast to real-time
quantification, and extra care should be
taken to avoid contamination during these
processes.
1.5.5. Internal standards and normal-
ization
RT-PCR can be “semi-quantitative” or
quantitative containing either a reference
gene for relative comparisons or a
competitor for quantification.  For relative
comparisons endogenous housekeeping
genes, supposed to be constitutively
expressed and minimally regulated, have
been used as reference genes. They have
also been used widely as endogenous
controls for quantitative real-time RT-PCR
assays. However, the expression of the
most commonly used housekeeping genes,
e.g. GAPDH and β-actin, have been found
to be highly variable (up to 30-70-fold)
both between individuals and between
biopses taken from the same patient
(Tricarico et al., 2002; Dheda et al., 2004;
Bas et al., 2004). Futhermore, GAPDH has
been shown to be upregulated in human
prostate carcinoma (Ripple and Wilding,
1995). Ribosomal RNAs which constitute
85-90 % of total cellular RNA have also
been used as internal controls and they
have been shown to be more reliable than
the housekeeping genes (Zhong and
Simons, 1999; Bas et al., 2004). However,
rRNAs can not be used for normalization of
mRNA samples and because of their high
expression levels they are not suitable
controls for genes with very low expression
levels.
Alternatively, a synthesized exo-
genous DNA or RNA sharing identical
PCR primer binding sites with target
mRNA molecules can be used as
competitors in qRT-PCR (Gilliland et al.,
1990; Wang et al., 1989; Becker-Andre and
Hahlbrock, 1989). An RNA competitor is
added to cDNA synthesis and a DNA
competitor can be added before or after the
RT step. The advantage of using DNA is
that DNA molecules are stable and easier to
handle than RNA molecules. However, a
DNA competitor measures only the
efficiency of the PCR step in contrast to an
RNA competitor, which also controls for
the variation in the RT step. A DNA
competitor has been shown to
underestimate the number of target mRNA
molecules by 10-fold when compared with
an RNA competitor (Dufva et al., 1995).
An even more accurate way is to add an
RNA competitor to the sample before RNA
extraction in order to control also for the
extraction step (Ylikoski et al., 1999). The
choice of the control molecule should be
carefully considered to optimize the
accuracy of each experiment.
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 minisequencing primer
 labelled dNTP
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Figure 3. The minisequencing principle. (1) Biotinylation of DNA fragments during
amplification using biotinylated primer. (2) Affinity-capture of two aliquots of amplified DNA
fragments on a streptavidin-coated solid support. (3) Denaturation of the captured double
stranded DNA fragments. (4) Identification of the variable nucleotides by annealing the
minisequencing primer, which is extended with a single labeled dNTP. (5) Measurement of
the incorporated label. Adapted from: Syvänen et al. Clin. Chim. Acta 226: 225-236 (1994).
                      
26
1.6. HEMATOGENOUS SPREAD OF
PROSTATE CANCER
The development of metastatic cancer is a
complex process, in which malignant cells
with invasive properties disseminate via
blood or lymphatics from the primary
tumor to the target organ. Once the
invading cells penetrate into the lymphatic
or vascular channels, they may grow there
or a single cell or clumps of cells may
detach and be transported within the
circulatory system. The cells may then
arrest at the capillary bed of the receptive
organs, extravasate into the organ
parenchyma, proliferate and establish a
metastasis (Fidler, 2002). Animal
experiments suggest that only about 0.01%
of all circulating cancer cells actually form
metastases (Liotta et al., 1974; Fidler and
Hart, 1982).
Radical prostatectomy of prostate
cancer is intended to provide complete
cure, but up to 30%-50% of these cases
recur, because prostate cancer cells from
the primary tumor have escaped prior or
during surgery to form metastases.
Conventional macroscopic imaging
techniques like bone scan and PSA are of
limited value for identification of these
cases and improved or new diagnostic and
prognostic modalities are needed to reliably
identify patients who have the best chance
of benefiting from surgical treatment.
Circulating cancer cells can be
identified in circulation of a patient by
certain methods. Immunocytological
methods have successfully been used in
several studies to identify tumor cells in
peripheral blood (Moss and Sanders, 1990;
Hamdy et al., 1992) bone marrow (Redding
et al., 1983; Pantel et al., 1996) and lymph
node (Trojani  e t  a l . ,  1987) .
Immunocytological studies for detection of
bone marrow micrometastases have
demonstrated an increased risk for
recurrent cancer of the breast, lung,
stomach and colon (Pelkey et al., 1996).
However, this method is dependent on the
availability of specific antibodies to cell-
surface antigens.
Since 1991, when Smith and
coworkers first reported the detection of
melanoma cells in circulation by RT-PCR
(Smith et al., 1991), several studies have
been performed on different cancers.
Primers for the genes of interest are
possible to design according the cDNA
sequence and RT-PCR is sensitive enough
for detection of rare cancer cells in
circulation.
Several qualitative RT-PCR studies of
the expression of PSA mRNA in
circulation of prostate cancer patients have
been done during last ten years. The
clinical sensitivity of the method
(percentage of patients with metastases
who tested positive using RT-PCR for
PSA) for peripheral blood averages 51%
(Table 5). In contrast, when bone marrow
was used as tissue source it averages 78%
(Corey et al., 1997b; Wood et al., 1994;
Deguchi et al., 1997; Melchior et al., 1997).
The false positive rate for assay of PSA
mRNA ranges from 0% to 40% (Table 5).
For PSM the clinical sensitivity averages
80% but at the same time the positive false
rate increases to 0%-96% (Table 6). The
detection limit in most RT-PCR assays for
PSA and PSM is 1 LNCaP cell
equivalent/106 blood mononuclear blood
cells regardless of the number of PCR
cycles, which in these studies rarely
exceeds 70 cycles. However, when nested
RT-PCR with total of 80 cycles was used,
the false positive rate was increased to
40%-100% (Henke et al., 1997; Smith et
al., 1995; McIntyre et al., 2000). A possible
explanation for the high false positive rates
is illegitimate transcripts detected by
extremely sensitive assays in normal blood
cells (Chelly et al., 1991).
The first studies which measured PSA
mRNA by RT-PCR in circulation used
autoradiography to measure the radio-
actively labeled PCR product or
densitometry to measure ethidium bromide
intensity (Sokoloff et al., 1996; O'Hara et
al., 1996). In these studies beta-actin was
used as a refence gene. A semiquantitative
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assay with an internal DNA control was
described in 1997, but no patient samples
were studied (Corey et al., 1997a). The first
quantitative studies for detection of PSA
mRNA used an internal RNA control and
time–resolved fluorometry (Verhaegen et
al., 1998; Ylikoski et al., 1999). An internal
RNA control has usually been used in
quantitative RT-PCR studies for PSA
(Verhaegen et al., 1998; Ylikoski et al.,
1999; Ylikoski et al., 2001b; Ylikoski et al.,
2002; Emmanouilidou et al., 2003; Kurek
et al., 2003). In real-time RT-PCR studies,
the quantification has been achieved with
an external calibration curve generated with
LNCaP cells or RNA isolated from LNCaP
cells (Gelmini et al., 2001; Straub et al.,
2001; Straub et al., 2003). Comparison of
different qRT-PCR assays for PSA is
difficult, because they all have used
different procedures. From these studies,
however, it can be concluded, that the
amount of PSA mRNA copies is higher in
blood of patients with metastatic PCa than
with organ confined disease. Although PSA
mRNA molecules has been found also in
control samples, the levels are lower than
in PCa patient samples (Ylikoski et al.,
1999; Ylikoski et al., 2001b; Straub et al.,
2001;  Ylikoski  et  a l . ,  2002;
Emmanouilidou et al., 2003).
RT-PCR has also been used to study
the effect of radical prostatectomy on the
levels of PSA mRNA in circulation. The
frequency of patients with CTCs and local
PCa was found to increase after radical
prostatectomy in 4 studies, but to decrease
in two other ones (Oefelein et al., 1996b;
Ogawa et al., 1999; Oefelein et al., 1999;
Okegawa et al., 2000; Straub et al., 2001;
Shariat et al., 2003b). The number of
patients with advanced cancer and CTCs in
their circulation was found to be unchanged
after radical prostatectomy in one and to
increase in another study (Okegawa et al.,
2000; Straub et al., 2001). It has been
speculated that radical prostatectomy may
increase the risk of hematogenous
dissemination of PCa (Ogawa et al., 1999)
and that post-operative PSA mRNA
positivity could be a predictor of disease
progression (Shariat et al., 2003a).
However, no correlation between post-
operative PSA positivity after RP and
Gleason score or stage of the disease in
several studies has been found (Oefelein et
al., 1996a; de Cremoux et al., 1997; Mejean
et al., 2000; Thomas et al., 2002; Shariat et
al., 2002). Longer follow-up and
standardized techniques are needed to
evaluate whether RT-PCR methods play a
role in “molecular staging” of prostate
cancer.
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Table 5. M
ethods , sensitivities and specificities of  qualitative RT -PCR for PSA
 m
RN
A
.  
Reference  
 
M
ethod  
 
Sensitivity  
 
PSA
 positivity 
(A
) 
PSA
 positivity 
(B)  
PSA
 positivity 
(C)  
PSA
 positivity 
(D
) 
M
oreno et al., 1992
 
RT-PCR, A
G
E, Sequencing  
N
D
 
N
D
 
N
D
 
33%
 (4/12)  
0%
 (0/17)  
K
atz et al., 1994
 
R T-PCR, A
G
E, Southern analysis , Chem
ilum
in. detection.  
1 LN
CaP/10e5 BM
C  
39%
 (25/65) 
N
D
 
78%
 (14/18) 
0%
 (0/65) 
Seid
en et al., 1994
 
RT-nested PCR, A
G
E,  Southern analysis  
10 LN
CaP / m
L blood  
6%
 (6/100)  
N
D
 
31%
 (11/35) 
0%
 (0/14) 
K
atz et al., 1995
 
RT-PCR, A
G
E, Southern analysis,  Chem
ilum
in.detection  
1  LN
CaP /10e5 BM
C  
35%
 (33/95) 
N
D
 
75%
 (6/8) 
N
D
 
Cam
a et a
l., 1995
 
RT-PCR, A
G
E, Southern analysis , Chem
ilum
in. detection  
N
D
 
34%
 (27/80) 
N
D
 
83%
 (5/6)  
0%
 (0/65)  
G
hossein et al., 1995
 
RT-PCR, A
G
E, Southern analysis  
1 LN
CaP /10e6 BM
C  
24%
 (6/25)  
N
D
 
34%
 (28/82)  
0%
 (0/27)  
G
alvan et al., 1995
 
RT-PCR, m
icrotiter based TRF  
1 LN
CaP /10e6 BM
C  
not tested 
N
D
 
N
D
 
N
D
 
Fadlon et al., 1996
 
RT-PCR, A
G
E, Southern analysis  
N
D
 
0%
 (0/2) 
N
D
 
10%
 (1/10)  
0%
 (0/5) 
Brandt et al., 1996
 
RT-nested PCR, A
G
E  
10pg to 1  ng  
N
D
 
N
D
 
6%
 (6/10) 
0%
 (0/4 BPH
)  
Zhang et al., 1997b
 
RT-nested PCR, A
G
E  
1 LN
CaP /10e6 BM
C  
13%
 (6/48)  
N
D
 
64%
 (7/11)  
0%
 (0/20) 
Corey et al., 1997b
 
RT-PCR, A
G
E 
1  LN
CaP /10e8 BM
C  
19%
 (12/63) 
N
D
 
46%
 (6/13)  
0%
 (0/20) 
Thiounn et al., 1997
 
RT -PCR, A
G
E, Southern analysis  
1 LN
CaP /10e6 BM
C  
22%
 (10/46) 
N
D
 
N
D
 
11%
 (17/145) 
Castaldo et al., 1997
 
RT- PCR, A
G
E, D
ot plot  
1 LN
CaP /10e6 BM
C  
23%
 (4/17)  
N
D
 
50%
 (3/6) 
0%
 (8/8) 
Ign
atoff et al., 1997
 
RT -PCR, A
G
E, radioactive PA
G
E  
N
D
 
21%
 (17/82) 
N
D
 
100%
 (11/11)  
0%
 (0/6)  
G
ao et al., 1999
 
RT -nested PCR, A
G
E  
1 LN
CaP /10e7 BM
C  
32%
 (27/85)  
42%
 (5/12) 
N
D
 
0%
 (0/22)  
M
illon et al., 1999
 
RT-PCR, A
G
E  
N
D
 
13%
 (4/31)  
N
D
 
N
D
 
N
D
 
M
cIntyre et al., 2000
 
RT -nested PCR (40+40  cycles ) , A
G
E  
2  LN
CaP /m
L blood  
N
D
 
N
D
 
N
D
 
40%
(4/10) 
M
cIntyre et al., 2000
 
RT-nested PCR (25+25  cycles), A
G
E  
4  LN
CaP /m
L blood  
N
D
 
N
D
 
N
D
 
0%
 (0/10)  
H
ara et al., 2002
 
RT-nested PCR, A
G
E  
1  LN
CaP /m
L blood  
2%
 (1/41)  
0%
 (0/2)  
50%
 (7/14)  
2%
 (1/71)  
G
ao et al., 2003
 
Epithelial cell enrichm
ent ,RT-nested PCR, PA
G
E, SY
BR G
old  1  LN
CaP /m
L blood  
80%
 (108/135)  
N
D
 
N
D
 
2 %
 (1/45) 
Scham
hart et al., 2003
 RT-nested PCR, A
G
E  
1  LN
CaP /m
L blood  
34%
 (14/34) 
N
D
 
N
D
 
N
D
 
K
urek et al., 2004
 
RT -nested PCR, A
G
E, Southern analysis  
1 LN
CaP /10e6 BM
C  
32%
 (76/238) 
40%
 (48/120)  
N
D
 
N
D
 
 N
D
= not determ
ined  
(A
)= blood sam
ples from
 patients w
ith local tum
ors  
(B)=  blood sam
ples from
 patients w
ith advanced tum
ors  
(C)=  blood sam
ples from
 patients w
ith m
etastatic tum
ors  
(D
)=blood sam
ples from
 controls  
A
G
E= agarose gel electrophoresis  
PA
G
E=polyacrylam
ide gel electro phoresis  
TRF=tim
e resolved fluorescence  
BPH
= benign prostatic hyperplasia  
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Reference
M
ethod
       D
etection lim
it or 
PSM
 m
RN
A
 
         PSM
 m
RN
A
 
PSM
 m
RN
A
       linear range 
positivity (A
)
         positivity (B)
positivity (C)
       
Israeli et al., 1994
RT-nested PCR      1 LN
CaP/10e6 M
CF-7 cells
72%
(13/18)                60%
 (9/15)
10%
 (4/39)
Israeli et al., 1995
RT-nested PCR      1 LN
CaP/10e6 M
CF-7 cells
63%
 (19/30)
            N
D
0%
 (0/16)
Loric et al., 1995
RT-nested PCR      1 LN
CaP/10e6 BM
C
44%
 (12/27) 
            85%
 (28/33)
0%
 (0/35), 0%
 (0/18 BPH
)
Eschw
ege et al., 1995
RT-nested PCR      N
D
60%
 (3/5)
            N
D
0%
 (0/6)
N
oguchi et al., 1997
RT-nested PCR      N
D
55%
 (38/69
            N
D
0%
 (0/40)
Zhang et al., 1997b
RT-nested PCR      1 LN
CaP/10e6 BM
C
16%
 (4/25)
            91%
 (10/11)
0%
 (0/11), 0%
 (0/9 BPH
)
G
ala et al., 1998
RT-nested PCR      2 LN
CaP/10e6 BM
C
            N
D
            
96%
 (24/25)
G
rasso et al., 1998
RT-nested PCR      N
D
43%
 (46/107)             91%
 (10/11)
0%
 (0/20), 0%
 (0/15 BPH
)
Lucotte et al., 1998
RT-nested PCR      1 LN
CaP/10e6 BM
C
64%
 (16/25)
            N
D
0%
 (0/35), 0%
 (0/15 BPH
)
Renneberg et al., 1999
RT-nested PCR      N
D
N
D
            N
D
N
D
Saim
oto et al., 1999
RT-nested PCR      N
D
85%
 (6/7)
            N
D
0%
 (0/6), 75%
 (3/4 BPH
)
O
kegaw
a et al., 1999
RT-nested PCR      N
D
pT2: 18%
 (3/17)         pT3: 64%
 (9/14), 
N
D
                N
1: 89%
 (8/9)
M
illon et al., 1999
RT-nested PCR      N
D
79%
 (38/48)
            N
D
71%
 (10/14)
M
cIntyre et al., 2000
RT-nested PCR      4 LN
CaP /m
L blood
19%
 (5/26)
            N
D
0 %
Loric et al., 2001
RT-nested PCR      N
D
55%
 (24/44)
            N
D
N
D
Llanes et al., 2002
RT-nested PCR      N
D
N
D
            N
D
38%
 (23/60)
H
ara et al., 2002
RT-nested PCR      1 LN
CaP/m
L blood
21%
 (12/58)
            N
D
3%
 (2/71)
Thom
as et al., 2002
RT-nested PCR      N
D
69%
            N
D
N
D
N
agao et al., 2002
RT-nested PCR      N
D
N
D
            N
D
N
D
A
dsan et al., 2002
RT-nested PCR      1LN
CaP/10e6 M
S cell
pT1: 0%
, pT2: 37%
    pT3: 42%
, N
1:48%
0%
 (0/20)
H
isatom
i et al., 2002
RT-nested PCR      N
D
N
D
            N
D
PSM
: 12.5%
, PSM
': 29%
V
arkarakis et al., 2003
RT-nested PCR      1 LN
CaP/10e6 BM
C
22%
 
           pT3: 60%
, T4: 95%
0%
 (0/20)
Chu et al., 2004
RT-nested PCR       0.0005 ng vs. 0.5 ng
59%
 (41/70) vs.          N
D
53%
 (10/19) vs. 4%
 (8/199)
    vs.  Real-tim
e PCR 
    27%
 (19/70)
(Em
m
anouilidou et al., 2004)    RT-PCR, Solution   500-5x 106 PSM
 copies
N
D
  
           N
D
N
D
                                                      hyhridization, 
     Chem
ilum
inescence
A
= blood sam
ples from
 patients w
ith local tum
ors
B= blood sam
ples from
 patients w
ith advanced or m
etastaic rum
ors
C= blood sam
ples from
 controls
Table 6.  M
ethods, sensitivities and specificities of RT-PCR studies for PSM
.
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2. AIMS OF THE STUDY
The aims of this study were:
1. To develop an RT-PCR method to detect
PSA mRNA-expressing cells in circulation
of prostate cancer patients.
2. To develop an RT-PCR method to detect
PSM mRNA-expressing cells in circulation
of prostate cancer patients.
3. To develop a quantitative method to
measure the expression levels of PSA
mRNA in blood of cancer patients and
healthy individuals and to compare the
expression levels of PSA mRNA at
different time points before and after
prostatic surgery and endocrine treatment
of PCa.
4. To develop a quantitative method to
measure the relative expression levels of
PSA and hK2 mRNAs in benign and
malignant prostatic tissue.
31
3. MATERIALS AND METHODS
3.1. SAMPLES
3.1.1. Cultured cells
LNCaP and DU-145 cell lines were
obtained from the American Type Culture
Collection. LNCaP cells were used for cell
spiking experiments to estimate the copy
number of PSA mRNA per cell (I, II) and
to evaluate the reproducibility of the
quantitative RT-PCR (III, IV). DU-145
cells were used as a negative control for
PSA and hK2 mRNA expression (IV).
Cells were cultured in RPMI 1640 medium
supplemented with 100 IU/mL penicillin,
0.1 µg/mL streptomycin (HyClone Europe
Ltd, Cramlington, UK), 10% fetal calf
serum (Flow Laboratories, UK), 2 mM
glutamine and 2.5 µg/mL amphotericin B
(GibcoBRL; Paisley, Scotland).
3.1.2. Blood samples
Blood samples from 55 patients with PCa,
29 with BPH, two with renal stones, and
three with other cancers (one renal cancer,
one testicular cancer, and one bladder
cancer) were obtained from the
Department of Urology, Helsinki Univer-
sity Central Hospital. Blood samples from
males less than 40 years of age and from
females were obtained from the
Hematology Laboratory of Helsinki
University Central Hospital (n=42 and
n=46, respectively) and from healthy
laboratory personnel (7 males and 6
females) (I, II, III). A single sample was
obtained from 25 PCa patients after
surgical therapy and from 4 BPH patients,
two patients with renal stones, and three
with other cancers and used in studies I
and II.
From 2 to 10 blood samples were
collected before, during and from 1 h to 6
months after biopsy or surgery from 30
PCa and from 25 BPH patients. These
patients included 15 men undergoing
needle biopsy, 17 treated by transurethral
resection of the prostate (TURP) because
of benign prostatic hyperplasia (BPH), 15
men treated by radical prostatectomy and 8
by orchiectomy. One patient receiving total
androgen blockade was also studied (III).
3.1.3. Tissue samples
Tissue samples of malignant prostate
(PCa) (n=13), normal prostate (n=3) and
hyperplastic prostate (n=14) were collected
at the Department of Urology, Malmö
University Hospital, Sweden and at the
Department of Pathology, HUCH (IV).
Two pairs of cancerous/benign tissue
samples were collected during radical
prostatectomy. Twelve PCa samples, one
normal prostate tissue and all BPH samples
were collected during TURP. Total RNA
and cDNA from normal prostatic tissue
and cDNA from the prostatic adeno-
carcinoma cell line (PC-3) were obtained
from Clontech (Palo Alto, CA).
3.2. DETECTION AND QUANTIFI-
CATION OF THE mRNA
3.2.1. RNA extraction
Blood samples (I, II, III) were drawn into
10 mL Vacutainer EDTA tubes (Becton
Dickinson, Rutherford, NJ). Erythrocytes
were hemolyzed within 2 h of
venipuncture by incubating 1 volume of
blood with 1.5 volumes of diethyl-
pyrocarbonate-treated water for 5 minutes
before collection of the nucleated cells by
centrifugation at 1200 x g for 10 min.
Total RNA was extracted from nucleated
cells, from exponentially growing cultured
cells and from fresh tissue specimens
according to the method of Chomczynski
and Sacchi (Chomczynski and Sacchi,
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1987) or with Phase Lock Gel (5 Prime --
>3 Prime, Boulder, CO). Total RNA
integrity was checked by formaldehyde gel
electrophoresis. In addition, RT-PCR with
specific β -globin and β -actin control
primers were used for blood and tissue
samples, respectively.
3.2.2. Determination of the
detection limit
The detection limit of the qualitative RT-
PCR method was established by spiking
blood samples with LNCaP cells, a prostate
carcinoma cell line expressing PSA.
LNCaP cells were cultured in RPMI-1640
medium as described earlier. The
leukocytes in the blood samples and the
LNCaP cells were counted and dilutions of
LNCaP cells were mixed with blood to
give 1-1000 LNCaP cells per 6 x 106
leukocytes/mL. Total RNA was isolated
and RT-PCR was done as described above.
3.2.3. Oligonucleotide primers
Oligonucleotide primers used for RT-PCR
of PSA, PSM and hK2 and for quantitative
detection of PSA and hK2 are shown in
Table 7. Primers for RT-PCR were chosen
from different exons to avoid amplification
of genomic DNA. The quality of the
isolated RNA was verified by control RT-
PCRs using β-globin or β-actin primers.
The sequences for the β-globin primers
were: 5’-ACC CAG AGG TTC TTT GAC
TC-3’(sense) and 5’-TCT GAT AGG CAG
CCT GCA CT-3’(antisense), and for β-
actin: 5’-CCC AGG CAC CAG GGC GTG
AT-3’(sense) and 5’-TCA AAC ATG ATC
TGG GTC AT-3’(antisense).
3.2.4. Internal standards
In the quantitative RT-PCR, mutated PSA
RNA (III) or cDNA as internal standard
(IS) (IV) were used. A mutated PSA
cDNA with a two-nucleotide deletion
(nucleotides 600 and 601, GenBank
Primer nt Exon (#) used inSequence
PSA outer sense
PSA outer antisense/ cDNA
PSA nested sense
PSA nested antisense 
PSM outer sense
PSM  outer antisense/ cDNA
PSM nested sense
PSM nested antisense
PSA/ hK2 cDNA
PSA/ hK2 sense
PSA/ hK2 antisense
PSA minisequencing
IS minisequencing
PSA/ IS minisequencing
hK2 minisequencing
CACAGGCCAGGTATTTCAGG
CCTTGATCCACTTCCGGTAA
TCCAATGACGTGTGTGCGCA
GTGTACAGGGAAGGCCTTTC
CAGATATGTCATTCTGGGAGGTC
AACACCATCCCTCCTCGAACC
CCTAACAAAAGAGCTGAAAAGCCC
ACTGTGATACAGTGGATAGCCGCT
GATGGTGTCCTTGATCCACT
CACTGGGGACCACCTGCTA
bio-CACTTCCGGTAATGCACCAC
GGTCACCTTCTGAGGGTGAAC
TTGGTCACCTTCTGAGGGTGA
AGAAACTTCAGTGTGTGG
AGGAGTCTTCAGTGTGTG
I, III
I, III
I, III *
I, III
II
II
II
II
IV
IV
IV
III
III
IV
IV
296-315
785-804
579-598
753-772
1266-1288
1893-1913
1587-1610
1798-1821
600-620
793-812
481-499
777-796
547-564
546-563
3
5
4
5
10
16
13/14
16
5
5
3
Accession numbers of PSA, PSM and hK2 are: NM_001648.2, BC025672 and BC005196.1.
* primer was 5´-biotinylated in study III
Table 7. PSA, hK2 and PSM primers used in studies I-IV.
minisequencing 
3H-nt
*dTTp
*dTTP
*dATP/*dTTP
*dATP
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NM_001648.2) in the vector pGEM-3 was
kindly provided by Dr. Alice Ylikoski,
Department of Biotechnology, University
of Turku. The plasmid was linearized and
used for RNA synthesis with the
AmpliScribe T7-kit (Epicentre Tech-
nologies Corporation, Madison, Wis-
consin). The RNA was purified with
Sephadex G-50 (Pharmacia NICK-
Columns, Pharmacia Biotech, Uppsala,
Sweden) and used as an internal RNA
standard (III).
For preparation of the internal cDNA
standard (IV), a substitution of A to T was
made in nucleotide 565 of PSA cDNA
(GenBank NM_001648.2) by site directed
mutagenesis (Ho et al., 1989). Mutated
PSA cDNA was cloned from nucleotide
481 to 812 into a pCR II plasmid vector
(Invitrogen).
3.2.5. RT-PCR
3.2.5.1. Qualitative assays
Nested qualitative RT-PCR assays were
used for PSA mRNA (I) and PSM mRNA
(II). One µg of total RNA was transcribed
into cDNA using the gene-specific
antisense PCR primer (Table 7) and AMV
(Promega, Madison, WI) or M-MLV
Reverse Transcriptase (GibcoBRL,
Gaithersburg, MD) according to
manufacturer’s instructions. The possible
contamination of the RNA samples with
cDNA was excluded by subjecting each
sample to the RT-reaction without RT-
enzyme before PCR. For PCR, five µl of
1/50 diluted cDNA (I) or 2 µl cDNA (II)
was amplified with the outer primers
(Table 7) in a 50-µl reaction volume. For
reamplification, five µl (I) or 2 µl (II) of
the first PCR product was further amplified
with the nested primers (Table 7) in a 50 µl
reaction volume. The amplification
conditions for PSA and PSM mRNA are
described in publications I and II,
respectively. The RT-PCR products were
separated in 1.5 % agarose gel and stained
with ethidium bromide. RNA isolated from
prostatic tissue was used as a positive
control and water as a negative control in
all experiments.
3.2.5.2. Quantitative assays
Total RNA from 1 mL of blood and 100
molecules of IS RNA (III) or 1 µg of total
RNA and 104 molecules of IS cDNA (IV)
were reverse transcribed with Super-
ScriptII RNase H- Reverse Transcriptase
(GibcoBRL Life Technologies) using the
gene-specific antisense primer (Table 7).
For the PCR reaction, one tenth (2 µl) of
cDNA with outer primers (Table 7) in a
50-µl reaction volume following the
amplification with the nested primers
(biotinylated sense and antisense, twenty
pmol and 100 pmol, respectively) in a 75-
µl reaction volume (III) or 30% of cDNA
using 80 pmol of sense primer and 16 pmol
of biotinylated antisense primer (Table 7)
in an 80-µl reaction volume (IV), was
amplified as described in III and IV. Ten
µl of the product was electrophoresed in a
2 % agarose gel and visualized by
ethidium bromide staining.
3.2.6. Restriction enzyme analysis,
cloning and sequencing of the PCR
products
In qualitative assays, the identity of the
PCR products was confirmed with Ava I
(I) or BstXI (II) restriction enzyme
digestion and sequencing of the product.
These enzymes have only one restriction
site within the PSA and PSM PCR
products, respectively. For sequencing, the
PCR products were cloned into a pCRII
plasmid vector (TA Cloning version 1.3;
Invitrogen). Plasmid DNA was sequenced
with Version 2.0 DNA Sequencing Kit
(United States Biochemical).
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3.2.7. Southern blot analysis
1.5 % agarose gel containing 16 negative
samples and one positive control sample
was blotted onto Hybond-N (Amersham
Intl, Amersham, UK) nylon membrane
according to the manufacturer´ s
instructions. The hybridization was carried
out at 65˚ C overnight in hybridization
solution containing 1 mol/L NaCl, 10%
dextran sulphate and 1% SDS. The
membrane was washed under high
stringency conditions. The sequenced
PCR-product, labeled by nick translation,
was used as a probe (I).
3.2.8. Solid-phase minisequencing
For quantification of PCR products the
biotinylated PCR product was captured on
a streptavidin coated scintillating micro-
titration plate (ScintiPlate, Wallac). The
bound DNA fragment was denaturated
with 50 mM NaOH leaving the bio-
tinylated antisense strand bound to the
well. Primer annealing and extension were
carried out in a minisequencing reaction
mixture containing the detection primer
and the appropriate 3H-labeled nucleotide
(Amersham) shown in Table 7. PCR
products from wild type and from IS were
detected in separate reactions. The
radioactivity was measured in a scintil-
lation counter. For each sample, the ratio
between the incorporated radioactive
nucleotides (PSA/IS or PSA/ hK2, in III
and IV, respectively) was calculated.
3.3. IMMUNOFLUOROMETRIC
 ASSAY FOR PSA
The DELFIA Prostatus PSA free/total kit
(Wallac), which simultaneously detects
free PSA and total PSA was used to
measure total PSA in plasma samples
collected at different time points before
and after prostatic operations (III).
3.4. STATISTICAL METHODS
The difference in serum PSA concen-
trations between patients who tested
positive or negative for PSA mRNA by
qualitative RT-PCR assay was analyzed by
Student’s t-test after logarithmic trans-
formation of the PSA values (I). The
difference in pre-or postoperative serum
PSA level, biopsy grade or Gleason score,
tumor grade or disease stage between PSA
mRNA positive and negative groups was
estimated by using the Mann-Whitney U-
test (III). The statistical significance of the
differences between PSA/hK2 mRNA
ratios (IV) in various sample groups was
calculated using the Mann-Whitney U-test
(IV).
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4. RESULTS AND DISCUSSION
4.1. RT-PCR ASSAYS FOR PSA, hK2
AND PSM mRNA
4.1.1. Qualitative assays
Qualitative RT-PCR assays were used for
detecting PSA- or PSM-expressing cells in
circulation of prostate cancer patients (I,
II). To determine the detection limit of the
assays, LNCaP cells were diluted into
blood sample from a healthy female donor.
PSA mRNA was detected by 30+30 cycles
of RT-PCR in samples containing 10-1000
LNCaP cells/mL of blood. Thus LNCaP
cells could be detected at a concentration
of 1.6 cells/106 blood leukocytes. This
corresponds to the sensitivity obtained in
other studies (Seiden et al., 1994;
Ghossein et al., 1995; Thiounn et al., 1997;
Castaldo et al., 1997).
All the dilutions containing 1-1000
LNCaP cells/mL of blood were positive
for PSM mRNA by 25+25 cycles of RT-
PCR. Thus the sensitivity of this method is
below 1 LNCaP cell/mL. All controls
without RT-enzyme were negative as well
as control samples without template. All
the negative patient samples were also
negative by Southern blot analysis, which
has a detection limit below that of
ethidium bromide staining. Total RNA
integrity was tested by control RT-PCR
reactions, in which all samples were
positive for β -globin or β-actin (pub-
lication II, Figure 1). Contamination of
RNA samples with prostatic RNA was
excluded by RT-PCR with PSA primers
before PSM mRNA RT-PCR (publication
II, Figure 2). The identity of the PCR
products was confirmed by restriction
enzyme analysis and sequencing of the
PCR product. The products had the
expected sequences of PSA or PSM.
4.1.2. Quantitative assays
Two different quantitative RT-PCR assays
for PSA mRNA were used to measure the
absolute amounts of PSA mRNA
molecules or the relative levels of PSA and
hK2 mRNA molecules in blood or tissue
samples (III, IV). In the first assay (III),
where absolute amounts of PSA were
measured, the primers amplified wild type;
GenBank Accession No NM_001648
(Lundwall and Lilja, 1987) and 5 out of the
13 known splicing variants of PSA mRNA,
which are M21896 (Riegman et al., 1988),
U17040 (Monne et al., 1994), PSA-RP1
(Heuze et al., 1999), AJ459782 and
AJ459783 (Heuze-Vourc'h et al., 2003).
Eight out of 13 splicing variants are not
ampl i f i ed  by  these  p r imers ;
AJ310937/M21897 and AJ310938 (Heuze-
Vourc'h et al., 2001), AJ512346 (Heuze-
Vourc'h et al., 2003), AF335477 and
AF335478 (David et al., 2002), alternative
spliced PSA by Tanaka et al. (Tanaka et
al., 2000), NM_145864 (Lundwall and
Lilja, 1987) and AJ459784 (Heuze-
Vourc'h et al., 2003). From M21896 and
PSA-RP1 a 636 bp transcript is produced,
but only transcripts of 194 bp, produced
from wild type and other variants were
detected by agarose gel electrophoresis
indicating absence or low expression levels
of the longer PSA mRNAs.
The internal standard used in the
quantitative PCR reaction competes with
the target analyte and thus it influences the
sensitivity of the method. The detection
limit of the first assay as defined by the
mean + 2 SD in negative samples was 7
copies of PSA mRNA when 100 molecules
of the internal standard were used. In
earlier studies different relationships
between IS and detection limit have been
observed, i.e. 50 copies PSA mRNA with
5000 copies of IS RNA (Ylikoski et al.,
2002) and 8 copies of squamous cell
carcinoma antigen mRNA with 20 copies
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plasmid DNA (Stenman et al., 2003).
Amplification of PSA mRNA was
observed in 42% of the 88 control samples,
and the highest concentration observed
was 25 copies/mL blood. Therefore the
cutoff level was defined as 26 copies/mL
blood and thus all control samples were
negative. The standard curve was linear
from 25 to 1000 copies when the number
of copies was plotted against the ratio of
PSA mRNA and IS RNA (Figure 4). The
reproducibility of the assay was evaluated
with RNA in dilutions corresponding to 1,
10, 100, and 1000 LNCaP cells per 107
blood leukocytes in 5 separate RT-PCR
assays. The interassay coefficient of
variation (CV%) in these samples was
26%, 29%, 13% and 27%, respectively.
The mean number (±SD) of PSA mRNA
molecules in one LNCaP cell was
calculated to be 887 (±393).
To measure the absolute concen-
trations of PSA mRNA, different mRNA
or DNA standards have been used.
Housekeeping genes like beta-actin or
GAPDH require different primers than the
target gene, and thus causes differences in
amplification efficiency (Sokoloff et al.,
1996; O'Hara et al., 1996). DNA standards
with a length difference like a small
insertion eliminate this problem (Corey et
al., 1997a). By using an internal RNA
standard, differing enough from the wild
type target sequence to allow specific
detection, the variations in reverse
transcription can also be controlled
(Verhaegen et al., 1998; Ylikoski et al.,
1999).
In the second assay for relative
quantification of PSA/hK2 mRNAs, 104
copies of internal standard was used. The
standard curve was determined by using
dilutions of PSA and hK2 cDNA together
with 104 molecules of IS. The assay was
linear from 102 to 106 molecules. The intra-
assay coefficient of variation (CV%) was
9-33% for PSA and 15-28% for hK2 in the
concentration range 102 to 106 mRNA
molecules. In this study the same primers
were used for PSA, the internal standard
and hK2, whereas different primer
sequences have been used for the target
genes in other studies (Ylikoski et al.,
2001b; Ylikoski et al., 2002). The mRNAs
of PSA and hK2 are similar enough to
permit simultaneous amplification with
identical PCR primers while still enabling
their separate detection. With this type of
experimental setup the relative amounts of
the two amplification products remain
unchanged throughout amplification and
reflect the proportions of mRNA
transcripts originally present in the sample
(Stenman et al., 1999).
The primers used in the second
assay amplified wild type NM_001648
(Lundwall and Lilja, 1987) and 6 out of the
13 known splicing variants of PSA mRNA;
M21896 (Riegman et al., 1988), U17040
(Monne et al., 1994), AJ459783 (Heuze-
Vourc'h et al., 2003), PSA-RP1 (Heuze et
al., 1999), AJ310938 (Heuze-Vourc'h et
al., 2001) and alternative spliced PSA by
Tanaka et al. (Tanaka et al., 2000) giving
315 bp, 458 bp or 757 bp pcr products.
Primers amplify also wild type hK2
mRNA BC005196 (Schedlich et al., 1987)
and nine out of the ten splicing variants of
hK2 mRNA, which are NM_005551.3,
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-1,0
-0,5
0,0
0,5
1,0
Number of PSA molecules
Lo
g 
of
 P
S
A
/ P
S
A
m
 m
R
N
A
 r
at
io
Figure 4. Standard curve of the quantitative
reverse-transcription-chain reaction (RT-
PCR) assay for prostate specific antigen
(PSA). PSAm = mutated PSA (IS).
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NM-001002231 and NM_001002232
(Olsson et al., 2004), S39329 (Riegman et
al., 1991), AF118745 and AF118746,
AF118747 (Liu et al., 1999), AY429509
(Michael et al., 2003) and AY429510
(Michael et al., 2003) giving 315 bp, 339
bp, 352 bp or 428 bp pcr products. One
splicing variant of hK2, that is AF336106
(David et al., 2002) is not amplified with
these primers. Only transcripts of 315 bp
from PSA and hK2 were detected by
agarose gel electrophoresis.
4.2. CLINICAL SAMPLES
4.2.1 PSA and PSM mRNAs in
circulation (I, II, III)
To study if the expression of PSA and
PSM mRNAs in blood could be used as a
marker for circulating malignant cells,
blood samples from PCa patients were
analyzed for PSA and PSM mRNA
expression (I, II). PSA mRNA was
detected in 50% (9/18) of PCa patients
with bone metastases, while 7 patients with
organ confined disease and 9 healthy
controls were negative (Table 8). In other
studies 27%-83% of blood samples from
PCa patients with metastases and 2%-80%
of blood samples of patients with local
PCa have been founded to be positive for
PSA mRNA. However, in these studies
1%-11% of the control samples were also
positive (Moreno et al., 1992; Katz et al.,
1994; Seiden et al., 1994; Katz et al., 1995;
Cama et al., 1995; Ghossein et al., 1995;
Henke et al., 1997; Melchior et al., 1997;
Zhang et al., 1997b; Hara et al., 2002;
Halabi et al., 2003). In three studies the
sensitivity was increased by using nested
Table 8. Clinical characteristics, PSA mRNA, PSM RNA, serum PSA concentrations and treatment
 of prostate cancer patients (studies I and III).
Age      PSA      PSM                Stage    Grade
    mRNA  mRNA
   serum PSA    Bone 
                         Scan
Treatment
(µg/L)
Metastatic disease
78 + nd   T2 G3 0.5    + estrogen
80 + + T3 G2       42.0    + orc.
66 + + T3 G3       85.0    + RP, orc.,estrogen
69 + + T4 G3       99.0    + TURP, Zoladex
73 + + T4 G2     143.0    + orc., TURP
78 + + T3 G2     317.0    + RP, orc., estrogen
81 + + T3 G2     846.0    + orc.
62 + + T2 G3     289.0    + RP, orc.
64 + + nd G3   1403.0    + estrogen
57 - + nd G3         0.5    + orc.
85 - + T3 G2     495.0    + TURP
62 - + nd G3 0.5    + orc.
71 - + nd G2       74.0    + orc.
75 - + nd G3         2.7    + estrogen
65 - + nd nd nd    + Flutamide
62 - - T3 G3   1180.0    + orc.
69 - - nd nd         1.0    + orc., estrogen
67 - - nd G3       36.0    + Zoladex
Organ confined disease
81 - + T1b G3         3.3    - TURP, orc.
79 - + T4 G1       47.0    - orc.
57 - + nd G4       17.0    - estrogen, Zoladex
73 - + T1b G1         0.5    - TURP
81 - - T3 G1         0.5    - orc., TURP
66 - - T3 G1 nd    - RP
74 - - nd G3         0.5    - Zoladex
RP= radical prostatectomy, orc.=orchiectomy, TURP=transurethral resection of the prostate,
nd= not determined
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PCR with 40+40 cycles, but this decreased
specificity dramatically, giving positive
results in 40%-100% of the control
samples (Smith et al., 1995; Henke et al.,
1997; McIntyre et al., 2000).
In the present study negative results in
patients with metastatic disease were
associated with successful endocrine
therapy and low levels of serum PSA, and
the correlation between serum concen-
trations of PSA and the presence of PSA
mRNA in peripheral blood was statistically
significant (I). PSA RT-PCR positivity has
also been found to correlate with capsular
penetration, stage and grade as well as to
the presence of skeletal metastases (Katz et
al., 1994; Cama et al., 1995; Kurek et al.,
2004; Ignatoff et al., 1997). A higher risk
for recurrence and decreased survival of
patients with androgen independent PCa
has also been shown to correlate with
positive RT-PCR for PSA mRNA (Katz et
al., 1995; Ghossein et al., 1997; Hara et al.,
2002; Halabi et al., 2003).
PSM mRNA was expressed in 14/17
(82%) PCa patients with bone metastases
and in 4/7 (57%) patients with organ con-
fined disease (Table 8). However, 5 out of
6 female controls and all 7 male controls
(92% of all controls) were also positive.
When the source of the false positive
results was studied it was founded to be
associated with isolated leukocytes,
whereas erythrocytes and platelets as well
as four different hematopoietic cell lines
(K-562, U-937, HL-60, Jurkat) were
negative for PSM mRNA RT-PCR. This
demonstrates true expression of PSM
mRNA in normal leukocytes, because all
control samples without reverse
transcriptase as well as RT-PCR reactions
without template were negative. In other
studies, 48%-95% and 16%-72% of
samples from patients with local and
metastatic disease were founded to be
positive, respectively (Israeli et al., 1994a;
Loric et al., 1995; Zhang et al., 1997b;
Grasso et al., 1998; Okegawa et al., 1999;
Adsan et al., 2002; Varkarakis et al.,
2003). In other studies 3%-96% of the
control samples have also been found to be
positive (Israeli et al., 1994a; Gala et al.,
1998; Millon et al., 1999; Llanes et al.,
2002; Hara et al., 2002; Schmidt et al.,
2003; Chu et al., 2004). In most of these
studies both PSM and PSM’ were detected
as well as PSML in some cases. In one
study 6% of the control samples were
found to express PSM, while 29 %
expressed PSM’ (Hisatomi et al., 2002). It
was concluded that PSM’ may induce false
positive results when PSM mRNA is used
for diagnosis of prostate cancer. Because
PSM is found to be expressed more
strongly in cancer than in benign prostatic
tissue (Sweat et al., 1998) and the ratio of
PSM to PSM’ has been found to be
increased in cancer (Su et al., 1995;
Schmittgen et al., 2003), it may be
speculated that primers excluding PSM’
might be more specific for studying
circulating cancer cells by RT-PCR. In
study II the primers of Israeli et al. (1994)
were used, and they detected all PSM
splicing variants as well as PSML.
The results obtained by PSA RT-PCR
confirmed that many patients with prostate
cancer have prostatic cells in peripheral
blood. However, in half of the patients
with advanced cancer treated by
orchiectomy or with estrogens, PSA
mRNA could not be detected, but in the
same samples PSM mRNA was expressed.
It is known that hormonal treatment of
prostate cancer will decrease the
expression of PSA at the protein and
mRNA level in prostatic tissue, but the
expression of PSM has been shown to be
upregulated after androgen-deprivation
therapy (Wright et al., 1996), which,
together with the fact that we detected
PSM expression also in normal blood
leukocytes may explain our results.
The results for PSM mRNA in white
blood cells and the finding that low levels
of PSA mRNA detectable by nested primer
RT-PCR is present in blood cells of non-
prostatic origin (Smith et al., 1995; Henke
et al., 1997; McIntyre et al., 2000) show
that the background expression of genes
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thought to be tissue-specific is a problem
when sensitive nested PCR methods are
used to detect cancer cells in circulation.
To control for the background
expression, a quantitative RT-PCR method
measuring the absolute concentrations of
PSA mRNA molecules in patient and
control samples was developed. The
sensitivity of our assay was high enough to
detect PSA mRNA in nearly half of the
control samples. It has been estimated that
there is one transcribed PSA or PSM
mRNA molecule per 100 000 white blood
cells and thus there would be 250
transcribed PSA or PSM mRNA molecules
in a 5 mL blood sample (McIntyre et al.,
2000). This means that the sensitivity of a
qualitative assay should be lower in order
not to detect these molecules and the
detection limit in quantitative assays
should be at most 50 copies/mL blood. In
study III, all 88 control samples contained
less than 26 PSA mRNA copies/mL of
blood, and therefore this was used as the
cutoff level. In another study using 100
copies/mL as a cutoff level 6% (2/34) of
the control samples were positive
(Ylikoski et al., 1999), while 5% (1/19) or
23% (3/13) blood samples from BPH
patients were were positive (Ylikoski et al.,
2002; Emmanouilidou et al., 2003). All the
positive control BPH patients had serum
PSA levels between 4-10 µg/L while BPH
patients with negative PSA mRNA had
serum PSA levels below 4 µg/L
(Emmanouilidou et al., 2003).
Prostatic surgery or endocrine
treatment induced clear changes in the
PSA mRNA level in blood. Immediately
after RP or TURP, PSA mRNA levels
increased in 27% and 29% of the samples,
respectively. Orchiectomy and biopsy also
caused a moderate increase in 25% and
13% of the samples, respectively. Radical
prostatectomy caused a doubling in the
number of positive samples in our study,
which is similar to results observed in
other studies (Oefelein et al., 1999; Ogawa
et al., 1999). TURP and biopsy also
increased the concentration of PSA mRNA
in circulation to the same extent as in
earlier studies (Moreno et al., 1997; Heung
et al., 2000; Hara et al., 2001; Price et al.,
1998). In most cases the PSA mRNA
levels dropped below the detection limit
within 1-3 days (Figure 5). This shows that
prostatic surgery causes a temporary
dissemination of prostatic cells into
circulation (Figure 6) as has been also
shown in other studies (Price et al., 1998;
Goldman et al., 1998; Oefelein et al.,
1996b). In one case treated by TURP the
level remained moderately elevated for 3
months declining thereafter. In one study,
post-operative positivity 6-8 weeks after
RP has been shown to predict disease
progression (Shariat et al., 2003b).
Previously Moreno et al. (2001) showed by
flow cytometry, that chemotherapy
reduced the number of circulating cancer
cells in PCa patients (Moreno et al., 2001).
Our study is the first to show that the
changes in concentrations of cancer cells in
circulation can be followed by quantitative
RT-PCR.
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4.2.2. The ratio of hK2/PSA mRNA in
prostatic tissue (IV)
Studies on protein expression by
immunohistochemistry have shown that
the PSA protein levels are lower in
prostate cancer tissue than in benign
prostatic tissue. In contrast, the levels of
hK2 protein have been found to increase in
cancer tissue or to decrease less than those
of PSA (Darson et al., 1999; Darson et al.,
1997; Magklara et al., 2000). On the RNA
level, the expression of hK2 has been
found to be increased in prostate cancer
tissue, while PSA is decreased or increased
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Figure 6. The amount of PSA molecules/mL
in PSA mRNA positive samples taken pre-
(0-) and postoperatively up to one hour (0+)
and 1-3 days after operation (RP, TURP,
orchiectomy, total androgen blockade or
biopsy).
Figure 5. Panel A: Number of prostate specific antigen (PSA) mRNA molecules/mL blood in
five postoperatively positive radical prostatectomy patients during 7 days of follow-up after
operation. Panel B: Plasma PSA concentrations of patients shown in panel A. Panel C shows the
content of PSA mRNA in blood during 2 weeks’ followup in two patients subjected to
orchiectomy. Panel D: Plasma PSA concentrations of orchiectomy patients shown in panel C.
Panel E shows PSA mRNA during 6 months’ follow-up in the five patients undergoing
transurethral resection of the prostate (TURP). Levels exceeding 25 molecules of PSA
mRNA/mL blood were considered positive shown as dash line. Notice that the time-scales are
non-linear and vary between the panels. The numbers on the graphs relate to cases mentioned in
the text of study III. 0- = preoperative sample, 0+ = postoperative sample.
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less than hK2 (Qiu et al., 1990; Herrala et
al., 2001; Fuessel et al., 2003; Gelmini et
al., 2003). In most of these studies the ratio
of hK2/PSA appears to increase in prostate
cancer compared to benign tissue. We
utilized a novel quantitative RT-PCR
method to measure the ratio of hK2 and
PSA mRNAs in benign and malignant
prostatic tissue. This method is designed to
accurately quantify the relative expression
levels of two homologous gene products in
the same reaction tube with the same RT-
PCR primers.
PSA and hK2 mRNAs were detected
in the normal prostate, in all 13 prostate
cancer samples and in 13 out of 14 BPH
samples. The range of the hK2/PSA ratios
was narrow, i.e., 0.38 – 0.50 in normal
prostatic tissue, 0.34 - 1.20 in BPH tissue
and 0.46 – 0.91 in cancerous tissue. In
LNCaP cells the hK2/PSA mRNA ratio
was 0.32. No expression of PSA or hK2
was detected the cell lines DU-145 and
PC-3. The median ratio of hK2/PSA
mRNA in normal and BPH tissue was 0.43
and 0.44, respectively, while that in WHO
grade 2 and 3 prostate cancer tissue was
0.63 and 0.73, respectively. The difference
between cancerous and benign tissues was
statistically significant, p=0.032 and
p=0.035 between G2 tumors and normal or
hyperplastic prostatic tissue, respectively,
and p=0.006 for G3 tumors compared to
normal or hyperplastic prostatic tissue
(Figure 7).
Although adjacent pieces of prostatic
tissues were subjected to histopathological
examination, a limitation of our method is
the lack of microscopic control of the
specimens extracted for RT-PCR analyses.
The samples were obtained during
palliative TURP and thus they may contain
both cancerous and benign epithelial
prostatic cells in various proportions. Thus
the true differences in hK2/PSA ratios
between cancerous and benign tissue are
probably larger than those measured. It
would be possible to study the ratio of
hK2/PSA expression more accurately by
using microdissection of prostatic tissue
under microscopic control. The present
study already shows that the method used
is suitable for accurate measurement of the
relative expression of these gene products
and the sensitivity is sufficient for
measurement of mRNA in minute samples.
As compared to real-time PCR, the
present method has the advantage of much
lower variation in the ratio between the
gene products measured, for example, 3-
fold rather than more than 1000-fold in the
ratio of PSA or hK2 to GADPH (Fuessel et
al., 2003). Part of the variation in real-time
PCR methods is probably caused by
variable content of epithelial and stromal
tissue, but differences in the amplification
of the target genes probably contributes to
the variation. The expression levels of
GAPDH and other housekeeping genes
have shown to be very variable, more than
30-fold in human blood mononuclear cell
culture and whole blood (Dheda et al.,
2004).
The mechanism causing differences in
expression of hK2 and PSA are not known
but various theories have been presented.
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Figure 7. hK2/PSA mRNA ratios in
normal (NP) and benign prostate
hyperplasia (BPH) tissue and WHO grade
2 (PCa G2) and 3 (PCa G3) prostatic
tumors as well as in LNCaP cell line. The
box denotes the 25th, 50th and 75th
percentiles and the whiskers represent the
10th and 90th percentiles. Circles mark
values outside these limits.
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Studies on the copy number of the PSA
and hK2 genes in tumor tissue have
suggested amplification of hK2 as a
possible cause (Herrala et al., 2001), but
because the genes are so closely located
(Diamandis and Yousef, 2002), it is
unlikely that amplification of only one of
these is a common phenomenon. No
mutations in the PSA gene have been
found in malignant prostate tissue (Baffa et
al., 1996). The expression of hK2 and PSA
are thought to be coordinated and regulated
by common and gene-specific enhancers
(Wei et al., 1998), but this is not supported
by experimental evidence (Herrala et al.,
2001). Thus the mechanisms causing the
change in expression levels of PSA and
hK2 remain to be explained.
Changes in expression of PSA and
hK2 in cancer may have implications for
the behavior of the tumor. In recent studies
PSA has been shown to cause degradation
of gelatin and type IV collagen in Matrigel
and activation of progelatinase A (MMP-2)
in a cell-free system (Pezzato et al., 2004).
It has also been shown that Zn(2+) in the
human prostate may suppress the invasion
and metastasis of prostate cancer cells
through inhibition of the proteolytic
activity of PSA (Ishii et al., 2004). In
prostate cancer the Zn(2+) levels are
markedly decreased as compared to normal
surrounding tissues (Zaichick et al., 1997),
suggesting that high concentrations of zinc
in prostatic tumors might even inhibit
tumor growth by inhibiting PSA activity.
On the other hand, PSA has been shown to
exert antiangionenic activity (Heidtmann et
al., 1999; Fortier et al., 2003). Thus a
reduction in PSA expression would be
compatible with increased aggressiveness.
HK2 is a highly active trypsin-like
proteinase (Bourgeois et al., 1997;
Lovgren et al., 1999), which has the
potential of participating in proteolytic
cascades contributing to invasive tumor
growth, (Frenette et al., 1997; Mullins and
Rohrlich, 1983). These findings suggest
that increase in the ratio of hK2/PSA
expression may favor aggressive tumor
growth, but direct evidence for this is
lacking. Our results showing an increased
hK2/PSA mRNA ratio in prostate cancer
compared to benign prostatic tissue
support this hypothesis.
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5. CONCLUSIONS
We have shown, that PSA mRNA can be
found in circulation of patients with
metastatic prostate cancer and that negative
results in patients with metastatic disease
are associated with successful endocrine
therapy and low levels of serum PSA. No
expression was found in negative control
samples, but when the sensitivity of the
method was increased by increasing the
number of PCR cycles, almost half of the
control samples became positive. We
therefore developed a quantitative RT-PCR
method and were able to set a cutoff limit
at which all control samples were negative.
With this method we found that the level
of PSA mRNA molecules in peripheral
blood increased after prostatic surgery,
suggesting a temporary dissemination of
prostatic cells. After the initial increase the
PSA mRNA levels decreased. However,
the preoperative levels only occasionally
correlated with other prognostic indicators
such as serum PSA, TNM classification,
grade and Gleason score. Thus our results
add further support to those of many other
studies showing that quantification of PSA
mRNA expressing cells in circulation of
cancer patients does not provide reliable
prognostic information in prostate cancer
patients.
We were able to show that PSM
mRNA is found in circulation of patients
with metastatic PCa, who had negative
result for PSA mRNA. Androgen ablation
is known to decrease the expression of
PSA in prostatic tissue while the
expression of PSM is upregulated and this
might explain these results. However, we
detected PSM expression also in normal
blood leukocytes. Additionally, the primers
used will amplify both PSM and its
splicing variant PSM’, which has been
shown to increase the frequency of false
positive results in control subjects. The use
of primers specific to PSM’ might have
reduced this problem. Another method,
which might reduce the false positive
results is a quantitative RT-PCR measuring
the ratio of PSM/PSM’ mRNAs. This ratio
has been shown to be increased in cancer
(Su et al., 1995).
Using an accurate quantitative RT-
PCR for measurement of the relative levels
of hK2 and PSA we showed that the ratio
of hK2/PSA is increased in prostate cancer
when compared to benign prostatic tissue.
Earlier studies have shown this phenom-
enon also on the protein level. The
mechanism causing the change in expres-
sion is not known. However, PSA has been
shown to exert antiangionenic activity, and
thus a reduction in PSA expression would
be compatible with increased aggres-
siveness. hK2 is on the other hand a highly
active trypsin-like proteinase with the
potential of participating in proteolytic
cascades contributing to invasive tumor
growth. These findings suggest that a
change in the ratio to hK2/PSA expression
may favor aggressive tumor growth. Thus
our method is of potential utility for
evaluation of the aggressiveness of pros-
tatic tumors.
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